---
document_datetime: 2023-09-21 20:16:28
document_pages: 51
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/veklury-h-c-5622-ii-0012-epar-assessment-report-variation_en.pdf
document_name: veklury-h-c-5622-ii-0012-epar-assessment-report-variation_en.pdf
version: success
processing_time: 69.0678331
conversion_datetime: 2025-12-22 13:28:08.417438
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

EMA/691378/2020 Committee for Medicinal Products for Human Use (CHMP)

## Type II variation assessment report

CHMP assessment report

Procedure No. EMEA/H/C/005622/II/0012

Invented name: Veklury

International non-proprietary name: remdesivir

Marketing authorisation holder (MAH): Gilead Sciences Ireland UC

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                                                                     | 3                                                                                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| 2. Overall conclusion and impact on the benefit/risk balance.....................                                                                                            | 3                                                                                                   |
| 3. Recommendations...................................................................................                                                                        | 6                                                                                                   |
| 4. EPAR changes .........................................................................................                                                                    | 6                                                                                                   |
| 5. Introduction............................................................................................                                                                  | 9                                                                                                   |
| 6. Clinical Efficacy aspects ..........................................................................                                                                      | 9                                                                                                   |
| 6.1. Final Day-28 mortality data by ordinal score of Study CO-US-540-5776 (NIAID-ACTT1)9                                                                                     |                                                                                                     |
| 6.2. Potential impact of Corticosteroids on treatment outcomes......................................                                                                         | 18                                                                                                  |
| 6.3. Interim WHO SOLIDARITY trial results - Remdesivir data........................................                                                                          | 20                                                                                                  |
| 6.3.1. Potential impact of Corticosteroids on treatment outcomes...................................                                                                          | 33                                                                                                  |
| 7. PRAC advice ..........................................................................................                                                                    | 35                                                                                                  |
| 8. Changes to the Product Information .....................................................                                                                                  | 36                                                                                                  |
| 9. Request for supplementary information................................................                                                                                     | 36                                                                                                  |
| 9.1. Major objections ................................................................................................                                                       | 36                                                                                                  |
| 9.2. Other concerns ..................................................................................................                                                       | 36                                                                                                  |
| 10. Assessment of the responses to the request for supplementary information ............................................................................................... | 37                                                                                                  |
| 10.1. Major objections...............................................................................................                                                        | 37                                                                                                  |
| 10.2. Other concerns                                                                                                                                                         | ................................................................................................ 40 |
| 11. Comments from member states ..........................................................                                                                                   | 49                                                                                                  |
| 12. Request for supplementary information..............................................                                                                                      | 50                                                                                                  |
| 12.1. Major objections...............................................................................................                                                        | 50                                                                                                  |
| 12.2. Other concerns                                                                                                                                                         | ................................................................................................ 50 |
| 13. References:.........................................................................................                                                                     | 51                                                                                                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Gilead Sciences Ireland UC submitted to the European Medicines Agency on 31 August 2020 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                                                                                                                                                                                            | Type    | Annexes affected   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.11.b              | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | Type II | II                 |

Submission of the final D28 mortality data by ordinal scale categories of Study CO-US-540-5776 (NIAIDACTT1), listed as a Specific Obligation ('SOB 13') in the Annex II of the Product Information, in order to confirm the efficacy and safety of Remdesivir in patients on Invasive Mechanical Ventilation (IMV) and Extracorporeal Membrane Oxygenation (ECMO). In addition, the MAH discusses the potential imbalance in the use of corticosteroids and effect modification in the study.

The requested variation proposed amendments to the Annex II to the EC Decision on the granting of the conditional marketing authorisation in order to remove 'SOB 013'.

## GLP/GCP inspections

N/A

## 2. Overall conclusion and impact on the benefit/risk balance

## Clinical discussion (1 st  round)

Remdesivir was given a 'conditional marketing authorisation' in the EU on 3 July 2020 for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen (oxygen via nasal cannula, non-invasive ventilation or high flow oxygen devices, IMV or ECMO).

The  pivotal  NIAID-ACTT1  (CO-US-540-5776)  study  was  a  randomised,  double-blinded  and  placebo controlled study conducted in hospitalised patients with COVID-19, with evidence of lower respiratory tract involvement. Treatment with Remdesivir or placebo, each on top of standard of care was for up to 10 days. The primary endpoint was time to recovery (defined as the first day of no longer being hospitalised or being hospitalised but no longer requiring medical care).

According to the inferential analysis, the median difference in time to recovery was 4 days favouring the Remdesivir group. In the primary endpoint Remdesivir was hence superior to placebo in the treatment of hospitalized participants with COVID-19 (HR: 1.32, 95% CI 1.12 to 1.55; p&lt;0.001).

In the stratum of patients with 'severe disease' (with pneumonia and need for supplemental oxygen), representing approximately 90% of patients in the study, the difference in median time to recovery was 12 versus 18 days, the RR was 1.37 (95% CI 1.15-1.163; p&lt;0.001). No difference in time to recovery was seen in the stratum of 'mild-moderate disease'.

<div style=\"page-break-after: always\"></div>

While the differentiation according to disease strata have been discussed and agreed by CHMP for the CMA, a higher degree of granularity with respect to subgroup analyses within the stratum of the severely ill patients was seen critical at the time of CMA in June 2020 and further data were requested, which are subject of this Specific Obligation ('SOB 013').

In the meantime, a number of studies, i.e. the Solidarity study  (1)  , the Recovery study  (2) , Tocilizumab trials (3)(4)(5)  and Bamlanivimab (6)  have become available to show that these subgroups would deserve to be carefully looked at separately, since the pathophysiology of the disease changes with severity and, hence, a uniform treatment response cannot be assumed since this is driven by the agent's mechanism of action, which, in turn, may be disease-stage dependent.

Moreover, no difference was seen in time to recovery in patients who started Remdesivir when they were already on IMV or ECMO (baseline ordinal score 7), the HR was 0.98 (95% CI 0.70-1.36). Therefore, CHMP requested the MAH to submit additional data including data on 28-day all-cause mortality as a SOB, in order to better characterise the efficacy and safety of Remdesivir in patients, particularly in this patient group.

The MAH has now submitted the final Day 28 mortality data by ordinal score category of the pivotal study (NIAID-ACTT1), listed as SOB 13 in the Annex II, in order to confirm the efficacy and safety of Remdesivir in patients on IMV or ECMO. In addition, data on the use of corticosteroids and potential effect modification in Study CO-US-540-5776 were provided.

With  respect  to  Day-28  all-cause  mortality,  the  data  indicate  a  numerically  lower  risk  of  mortality  for Remdesivir in the overall population (both strata). However, this effect is mainly driven by patients requiring supplemental oxygen (baseline ordinal score of 5). Between-group results vary considerably according to baseline  disease  severity.  Neither  for  the  subgroup  with  a  baseline  ordinal  score  of  6  (non-invasive ventilation or high flow oxygen devices), nor for the subgroup with a baseline ordinal score of 7 (IMV or ECMO) a beneficial effect was conclusively seen: not for time to recovery, and neither for mortality.

In contrast, the results may be indicative of a negative trend in patients on IMV or ECMO (21.9% vs. 19.3%, respectively, RR 1.13; CI 0.67, 1.89).

In addition, the interaction tests between treatment effect and baseline ordinal score indicate a reduced or even lack of efficacy in the higher baseline ordinal scores (of 6 and 7) with respect to time to recovery and mortality.

These results would substantiate the concept of a temporal window of opportunity for an antiviral substance, such as Remdesivir, in COVID-19. Based on the currently available data this window appears to be limited to patients in need of supplementary oxygen at high risk for disease progression but not yet suffering from more severe pulmonary affection.  An  effect  of  Remdesivir  has  not  be  observed  in  patients  with  more advanced disease, as their disease course is rather driven by the host inflammatory response than by the virus, and hence Remdesivir as antiviral drug may not have a benefit here.

These  considerations  are  further  supported  by  the  recently  published  interim  results  of  the  WHOSOLIDARITY trial that also indicate a negative trend in mortality in this patient population hospitalised for COVID-19. While in the analysis of the 28-day in-hospital mortality data in the overall population no definite effect of Remdesivir on mortality was seen (RR 0.95 [0.85-1.11, p=0.50), subgroup analyses stratified by ventilation status at randomisation did also show a negative trend in mortality in patients already ventilated at baseline (RR: 1.20, CI [0.89-1.64, p = 0.24] compared to patients not receiving ventilation at study entry (RR: 0.86 [0.72-1.04) although data did not reach statistical significance. Even when considering the uncertainties concerning subgroup analyses due to their limited sample sizes, the analyses indicate that Remdesivir may have no benefit in the population of critically ill COVID-patients.

<div style=\"page-break-after: always\"></div>

However, comparisons of the D28 mortality data from different trials should be interpreted with some caution,  due  to  questionable  comparability  of  ventilation  status  between  the  different  trials  and  also differences in the mortality endpoints (in-house mortality in Solidarity versus all-cause mortality in the NIAID trial).

## Clinical discussion (2 nd  round):

During the assessment of this variation a major objection (MO) was raised at the first round, in which the MAH was explicitly asked to justify a favourable risk-benefit profile based on the overall available evidence in patients on IMV or ECMO when starting Remdesivir. However, in the response the MAH only addressed the potential risk/harmful effects of remdesivir in the subgroup of patients on IMV or ECMO at baseline but neither the observerd missing benefit on Time to recovery (TTR), the primary efficacy endpoint of this study, nor on mortality in patients with baseline ordinal score 7.

The analyses of efficacy in the subset of participants on invasive mechanical ventilation or ECMO at baseline do not indicate any benefit of RDV, neither for the time to recovery (HR: 0.98; CI 0.70, 1.36), nor for mortality (RR: 1.13; CI 0.67, 1.89; p = 0.652).

This is further supported by the requested additional mortality analyses for specific subgroups. The hazards of death in the subgroup of ventilated patient, i.e. those on non-invasive ventilation, invasive mechanical ventilation or ECMO at baseline (HR: 1.12; CI 0.7, 1.82) and for patients on non-invasive ventilation (HR: 1.11; CI 0.32, 3.83), were both similar to the results seen in patients on IMV/ECMO (HR: 1.13; CI 0.67, 1.89; p = 0.652), suggesting that being ventilated at the time of RDV treatment initiation may not be beneficial. Results for the primary endpoint 'Time to Recovery' for the subgroup of ventilated patients (noninvasive and invasive/ECMO) are not yet available. Hence, it remains unclear if RDV has a beneficial effect in this patient population.

In addition, the statistically significant effect of RDV treatment, when given during the first 10 days after symptom onset (RR: 1.37 CI. 1.14; 1.64) further supports that there is a temporal 'window of opportunity' for RDV treatment at an earlier disease stage, while deterioration to IMV/ECMO has been reported to occur later in COVID-19.

It is also noted that based on these subgroup analyses and clinical experience, several national treatment guidelines  and  learned  societies  in  the  EU  already  do  not  recommend  treatment  with  RDV  in  patients receiving IMV or ECMO at baseline and with onset of symptoms more than (5 to) 10 days ago.

## Overall conclusion:

No difference was seen in time to recovery in patients who started Remdesivir when they were already on IMV or ECMO (baseline ordinal score 7), the HR was 0.98 (95% CI 0.70-1.36). Therefore, CHMP requested the MAH to submit additional data including data on 28-day all-cause mortality as 'SOB 013', in order to confirm the efficacy and safety of Remdesivir in patients on IMV or ECMO. The provided data failed to confirm the efficacy of RDV in patients on IMV or ECMO at baseline, in terms of mortality (RR: 1.13; CI 0.67, 1.89; p = 0.652).

Risk-benefit considerations triggered by the inconsistency of beneficial effect at primary and secondary endpoints  analyses  among  the  overall  study  population  and  subjects  of  patients  on  IMV  or  ECMO  are regarded as credible because of the biological plausibility, and directional consistency. In addition, these results are corroborated by evidence coming from other independent trials  (1)(2)(3)(4)(5)(6) .

The CHMP concluded that taking the lack of evidence to support benefit in this subgroup into account, the B/R in this subgroup of patients has not been shown to be positive.

Therapy of patients on IMV/ECMO at baseline should no longer be indicated for RDV. Therefore, the wording of the therapeutic indication is revised accordingly by restricting the target population in section 4.1 of the

<div style=\"page-break-after: always\"></div>

SmPC. Section 5.1 of the SmPC is also updated to reflect the  study results, and the Annex II is updated to remove the completed specific obligation ('SOB 013'). The package leaflet is updated accordingly.

## 3. Recommendations

Based on the review of the submitted data, this application regarding the following change:

| Variation requested   | Variation requested                                                                                                                                                                                                                                                                            | Type    | Annexes affected   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.11.b              | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | Type II | I, II and IIIB     |

Update of section 4.1 of the SmPC to change the indication as a result of the assessment of the final D28 mortality data by ordinal scale categories of Study COUS-540-5776 (NIAID-ACTT1), listed as a Specific Obligation ('SOB 013') in the Annex II of the Product Information, in order to confirm the efficacy and safety of remdesivir in patients on Invasive Mechanical Ventilation and Extracorporeal Membrane Oxygenation (IMV/ECMO).  Consequently  section  5.1  of  the  SmPC  is  also  updated  to  reflect  the  final  study  results. Furthermore,  Annex  II  is  updated  to  remove  the  completed  specific  obligation.  The  package  leaflet  is updated accordingly.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB are recommended as follows:

Taking the lack of evidence for a benefit in patients on IMV/ECMO into account, the B/R in this subgroup has not been shown to be positive. Therefore, the indication is restricted and patients on IMV/ECMO at baseline are excluded from the therapeutic indication of RDV. The wording of SmPC Section 4.1 is amended as follows:

- Veklury  is  indicated  for  the  treatment  of  coronavirus  disease  2019  (COVID-19)  in  adults  and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental  oxygen (low-  or  high-flow  oxygen  or  non-invasive  ventilation  at  start  of treatment) (see section 5.1).

In addition,  section 5.1 of the SmPC is updated with the data from the post-hoc analysis of 28-day mortality by ordinal scale.

Annex II is updated to remove the completed specific obligation ('SOB 013').

The Package Leaflet is updated accordingly.

## 4. EPAR changes

The table in Module 8b of the EPAR will be updated as follows:

<div style=\"page-break-after: always\"></div>

## Scope

Please refer to the Recommendations section above

## Summary

Please refer to Scientific Discussion Veklury/H/C/005622/II/0012

<div style=\"page-break-after: always\"></div>

## Annex: CHMP assessment comments on the type II variation

<div style=\"page-break-after: always\"></div>

## 5. Introduction

Veklury received a 'conditional marketing authorisation' in the EU on 3 July 2020 for the treatment of COVID-19 in  adults  and  adolescents  from  12  years  of  age  with  pneumonia  who  require  supplemental oxygen, because the benefits to these severely ill patients outweigh the risks of making the medicine available despite having less complete data than normally expected.

At  the  time  of  authorisation,  CHMP  requested  the  MAH  to  submit  additional  data,  either  as  specific obligations (SOB) or PAMs.

The  current  variation  concerns  the  assessment  of  SOB  No.  13,  which  was  agreed  on  at  the  time  of conditional marketing authorisation of Veklury. The MAH has now submitted the publication of the final results of Study CO-US-540-5776 (NIAID-ACTT1; Beigel et al ., 2020 DOI: 10.1056/NEJMoa2007764)  (7) that includes the final D28 mortality data by ordinal scale categories, listed as a Specific Obligation No. 13 in the Annex II of the EPAR - Product Information, in order to confirm the efficacy and safety of Remdesivir in patients on IMV or ECMO. In addition, data on the potential imbalance in the use of corticosteroids and effect modification in Study CO-US-540-5776 were provided.

## 6. Clinical Efficacy aspects

## 6.1. Final Day-28 mortality data by ordinal score of Study CO-US-540-5776 (NIAID-ACTT1)

## Methods - analysis of data submitted

At the time of conditional marketing authorisation, data on the key secondary endpoint 'Mortality at D28' were not available, as not all patients did have their 28-day visit. Now the publication of the final results of the NIAID-ACTT1 study, including the final D28 mortality data, have been submitted by the MAH {Beigel et al, 2020}. These are summarized below, supplemented with information from the study report, which was also submitted. However, the assessment of the complete CSR will be subject to the renewal procedure.

## Statistical methods:

Mortality through Day 15 and Day 29 was analysed as a time-to-event endpoint and presented with median time-to-event along with 95% CIs for each treatment group along with the HR estimate and stratified logrank p-values. Differences in time-to-event endpoints by treatment were summarized with KM curves. Analyses of mortality were performed on the ITT- and As Treated-Populations. Any participants who were lost  to  follow-up  or  terminated  early  prior  to  death  were  censored  at  the  day  of  their  last  observed assessment or last captured event (e.g., the end date of an AE). If it was learned that a participant who terminated  early  had  subsequently  died  prior  to  Day  29,  then  the  participant  was  classified  as  dead. Participants who completed follow-up were censored at the earliest of their Day 29 visit and actual Day 29. Deaths that occurred after Day 29 were censored at Day 29.

## CHMP's comment

Standard time to event methods were applied that are appropriate.

<div style=\"page-break-after: always\"></div>

## Results

## Mortality (CSR):

Mortality status at day 29 was available for 508/541 patients in the RDV group and 499/521 patients in the Placebo group.

Table 1: Mortality data of patients with known mortality status at D29

|                                                                          | Overall                          | Overall                          | Mild-Moderate Disease            | Mild-Moderate Disease            | Severe Disease                   | Severe Disease                   |
|--------------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                                          | RDV (N=541)                      | Placebo (N= 521)                 | RDV (N =55)                      | Placebo (N = 50)                 | RDV (N=486)                      | Placebo (N = 471)                |
| Mortality among all participants                                         | Mortality among all participants | Mortality among all participants | Mortality among all participants | Mortality among all participants | Mortality among all participants | Mortality among all participants |
| No.with known mortality status at Day 29 (% of total)                    | 508 (93.9)                       | 499 (95.8)                       | 51 (92.7)                        | 46 (92.0)                        | 457 (94.0)                       | 453 (96.2)                       |
| No. of deaths by Day 29 (% of no. with known mortality status at Day 29) | 59 (11.6)                        | 77 (15.4)                        | 2 (3.9)                          | 3 (6.5)                          | 57 (12.5)                        | 74 (16.3)                        |

In the ITT Population, the mortality rate (95% CI) of participants by Day 15 was numerically lower in the RDV 10-day group (n = 541) than in the placebo group (n = 521) (7% [5%, 9%] versus 12% [9%, 15%], respectively).The mortality rate (95% CI) of participants by Day 29 was numerically lower in the RDV 10day group than in the placebo group) (11% [9%, 15%] versus 15% [12%, 19%], respectively). Results were similar in the As Treated Population.

In the ITT Population, the risk of death by Day 15 was significantly lower in the RDV 10-day group compared with the placebo group (HR 0.55; 95% CI: 0.36, 0.83; p = 0.004) (Table 2). The risk of death by Day 29 was numerically lower in the RDV 10-day group compared with the placebo group (HR 0.73; 95% CI: 0.52, 1.02; p = 0.066). Results were similar in the As Treated Population.

In the ITT Population, the median time to death through Day 15 or Day 29 was not estimable for either treatment group.

Table 2: Deaths by Day 15 or Day 29 by treatment group ITT and as treated

|                       |           | Remdesivir   | Remdesivir   | Remdesivir      | Remdesivir   | Placebo   | Placebo   | Placebo         | Placebo     |
|-----------------------|-----------|--------------|--------------|-----------------|--------------|-----------|-----------|-----------------|-------------|
| Analysis Population   | Study Day | N            | n            | Mortality Ratea | Rate 95% CI  | N         | n         | Mortality Ratea | Rate 95% CI |
| ITT                   | Day 15    | 541          | 35           | 0.07            | 0.05,0.09    | 521       | 61        | 0.12            | 0.09,0.15   |
| Population            | Day 29    | 541          | 59           | 0.11            | 0.09,0.15    | 521       | 77        | 0.15            | 0.12,0.19   |
| As Treated Population | Day 15    | 532          | 35           | 0.07            | 0.05, 0.09   | 516       | 61        | 0.12            | 0.09, 0.15  |
| As Treated Population | Day 29    | 532          | 59           | 0.11            | 0.09, 0.14   | 516       | 77        | 0.15            | 0.12, 0.19  |

N =Number of subjects in the specified treatment group and analysis population.

n=Number ofsubjectsin agiventreatmentgroupwhodied bythegiventimepoint

a Mortalityrate is theKaplan-Meierestimate.

Source:Section15.1,Table59

<div style=\"page-break-after: always\"></div>

## Ad Hoc Subgroup Analyses for Mortality (CSR)

Ad hoc subgroup analyses were performed for mortality by actual disease stratum or ordinal score. In the analyses according to actual disease stratum, the percentages of deaths among participants with known mortality status at Day 29 in the RDV 10-day group compared with those in the placebo group were as follows (Table 3):

## Severe disease:

- 12.5% (57 of 457 participants) versus 16.3% (74 of 453 participants), respectively.

## Mild-to-moderate disease:

- 3.9% (2 of 51 participants) versus 6.5% (3 of 46 participants), respectively.

Table 3: Mortality rates by treatment group and actual disease severity (ITT population)

|                                                                                   | Overall                                                        | Overall                                                        | Mild-Moderate Disease                                          | Mild-Moderate Disease                                          | Severe Disease                                                 | Severe Disease                                                 |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                                   | RDV (N= 541)                                                   | Placebo (N = 521)                                              | RDV (N =55)                                                    | Placebo (N = 50)                                               | RDV (N = 486)                                                  | Placebo (N =471)                                               |
| Mortality among all participants                                                  | Mortality among all participants                               | Mortality among all participants                               | Mortality among all participants                               | Mortality among all participants                               | Mortality among all participants                               | Mortality among all participants                               |
| No.with known mortality status at Day 29 (% of total)                             | 508 (93.9)                                                     | 499 (95.8)                                                     | 51 (92.7)                                                      | 46 (92.0)                                                      | 457 (94.0)                                                     | 453 (96.2)                                                     |
| No.of deaths byDay 29 (% of no.with known mortality status at Day 29)             | 59 (11.6)                                                      | 77 (15.4)                                                      | 2 (3.9)                                                        | 3 (6.5)                                                        | 57 (12.5)                                                      | 74 (16.3)                                                      |
| Mortality among participants crossing over from placebo to RDV                    | Mortality among participants crossing over from placebo to RDV | Mortality among participants crossing over from placebo to RDV | Mortality among participants crossing over from placebo to RDV | Mortality among participants crossing over from placebo to RDV | Mortality among participants crossing over from placebo to RDV | Mortality among participants crossing over from placebo to RDV |
| No. unblinded (% of total)                                                        | 16 (3.0)                                                       | 35 (6.7)                                                       | 0 (0.0)                                                        | 1 (2.0)                                                        | 16 (3.3)                                                       | 34 (7.2)                                                       |
| No.crossoversfrom placebo to RDV arm (% of no. unblinded)                         |                                                                | 26 (74.3)                                                      |                                                                | 1 (100.0)                                                      |                                                                | 25 (73.5)                                                      |
| No.with known mortality status at Day 29a(% of no. crossovers)                    |                                                                | 26 (100.0)                                                     |                                                                | 1 (100.0)                                                      |                                                                | 25 (100.0)                                                     |
| No. of deaths by Day 29 (% ofno.crossovers with known mortality status at Day 29) |                                                                | 3 (11.5)                                                       |                                                                | 0 (0.0)                                                        |                                                                | 3 (12.0)                                                       |

Number with known mortality status at Day 29 is the number of participants who have data for a day on or after Day 26 or who are known to be deceased. Day 26 represents the beginning of the visit window for the Day 29 visit.

Source:Section15.1,AddendumTable16.2

In analyses according to baseline ordinal scores 4, 5, 6, and 7, the greatest difference in percentages of deaths among participants with known mortality status at Day 29 in the RDV 10-day group compared with that in the placebo group was observed in the subgroup with baseline ordinal score 5 (4.1% [9 of 222 participants] versus 12.8% [25 of 195 participants], respectively; HR [95% CI] = 0.30 [0.14, 0.64], p &lt; 0.001) (Table 5). In none of the other subgroups (baseline ordinal scale 4, 6 and 7) a significant effect of Remdesivir on mortality was seen. In patients with baseline ordinal score 7, the percentage of death was larger at D29 in the Remdesivir group compared to the placebo group (22% [28 of 131 participants] vs. 19.6% [29 of 154 patients] respectively HR [95%] = 1.31 [0.67, 1.89].

<div style=\"page-break-after: always\"></div>

Table 4: Mortality rates by treatment group and baseline ordinal score (ITT population)

| Table 28.                                                               | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   | CO-US-540-5776:MortalityRatesbyTreatmentGroup andBaselineOrdinalScore(ITTPopulation)   |
|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
|                                                                         | Overall                                                                                | Overall                                                                                | Baseline Ordinal Score4                                                                | Baseline Ordinal Score4                                                                | Baseline Ordinal Score 5                                                               | Baseline Ordinal Score 5                                                               | Baseline Ordinal Score 6                                                               | Baseline Ordinal Score 6                                                               | Baseline Ordinal Score7                                                                | Baseline Ordinal Score7                                                                |
|                                                                         | RDV (N =541)                                                                           | Placebo (N = 521)                                                                      | RDV (N =75)                                                                            | Placebo (N=63)                                                                         | RDV (N =232)                                                                           | Placebo (N =203)                                                                       | RDV (N=95)                                                                             | Placebo (N=98)                                                                         | RDV (N =131)                                                                           | Placebo (N =154)                                                                       |
| Mortality among all participants                                        | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       | Mortality among all participants                                                       |
| No.with known mortality status at Day29(%of total)                      | 508 (93.9)                                                                             | 499 (95.8)                                                                             | 72 (96.0)                                                                              | 59 (93.7)                                                                              | 222 (95.7)                                                                             | 195 (96.1)                                                                             | 87 (91.6)                                                                              | 97 (99.0)                                                                              | 127 (96.9)                                                                             | 148 (96.1)                                                                             |
| No.of deaths by Day 29 (% of no. with known mortality status at Day 29) | 59 (11.6)                                                                              | 77 (15.4)                                                                              | 3 (4.2)                                                                                | 3 (5.1)                                                                                | 9(4.1)                                                                                 | 25 (12.8)                                                                              | 19 (21.8)                                                                              | 20 (20.6)                                                                              | 28 (22.0)                                                                              | 29 (19.6)                                                                              |
| Hazard ratio (95% CI)                                                   | 0.73 (0.52, 1.02)a                                                                     | 0.73 (0.52, 1.02)a                                                                     | 0.82 (0.17, 4.07)b                                                                     | 0.82 (0.17, 4.07)b                                                                     | 0.30 (0.14, 0.64)b                                                                     | 0.30 (0.14, 0.64)b                                                                     | 1.02 (0.54, 1.91)b                                                                     | 1.02 (0.54, 1.91)b                                                                     | 1.13 (0.67, 1.89)b                                                                     | 1.13 (0.67, 1.89)b                                                                     |
| P-value                                                                 | 0.066c                                                                                 | 0.066c                                                                                 | 0.809d                                                                                 | 0.809d                                                                                 | pl00'0>                                                                                | pl00'0>                                                                                | 0.949d                                                                                 | 0.949d                                                                                 | 0.652d                                                                                 | 0.652d                                                                                 |
| Mortality among participants crossing over from placebo toRDv           | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          | Mortality among participants crossing over from placebo toRDv                          |
| No. unblinded (% of total)                                              | 16 (3.0)                                                                               | 35 (6.7)                                                                               | 0 (0.0)                                                                                | 2 (3.2)                                                                                | 1 (0.4)                                                                                | 6 (3.0)                                                                                | 9 (9.5)                                                                                | 8 (8.2)                                                                                | 6 (4.6)                                                                                | 19 (12.3)                                                                              |
| No. crossovers from placebo to RDV arm (% of no.unblinded)              |                                                                                        | 26 (74.3)                                                                              |                                                                                        | 1 (50.0)                                                                               |                                                                                        | 4 (66.7)                                                                               |                                                                                        | 5 (62.5)                                                                               |                                                                                        | 16 (84.2)                                                                              |
| No.with known mortality status at Day 29 (% of no. crossovers)          |                                                                                        | 26 (100.0)                                                                             |                                                                                        | 1 (100.0)                                                                              |                                                                                        | 4 (100.0)                                                                              |                                                                                        | 5 (100.0)                                                                              |                                                                                        | 16 (100.0)                                                                             |
| No. of deaths by Day 29 (% ofno.crossovers with                         |                                                                                        | 3 (11.5)                                                                               |                                                                                        | 0 (0.0)                                                                                |                                                                                        | 2 (50.0)                                                                               |                                                                                        | 0 (0.0)                                                                                |                                                                                        | 1 (6.3)                                                                                |

|                                | Overall      | Overall           | Baseline Ordinal Score4   | Baseline Ordinal Score4   | Baseline Ordinal Score5   | Baseline Ordinal Score5   | Baseline Ordinal Score 6   | Baseline Ordinal Score 6   | BaselineOrdinal Score 7   | BaselineOrdinal Score 7   |
|--------------------------------|--------------|-------------------|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------|----------------------------|---------------------------|---------------------------|
|                                | RDV (N =541) | Placebo (N = 521) | RDV (N =75)               | Placebo (N=63)            | RDV (N =232)              | Placebo (N =203)          | RDV (N=95)                 | Placebo (N =98)            | RDV (N =131)              | Placebo (N =154)          |
| knownmortalitystatusat Day 29) |              |                   |                           |                           |                           |                           |                            |                            |                           |                           |

Number with known mortality status at Day 29 is the number of participants who have data for a day on or after Day 26 or who are known to be deceased. Day 26 represents the beginning ofthe visit window for the Day 29 visit.

b HR is the ratio of the hazard of Death in cach treatment group estimated from the Cox model. The ratio is remdesivir to placcbo

HR is the ratio of the hazard of Death in cach treatment group estimated from the stratified Cox model. The ratio is remdesivir to placcbo.

P-value calculated using the stratified log-rank test

Sourcc: Scction 15.1,Table 6l,Addendum Table16.1,and AddendumTable 22

P-value calculated using the log-rank tcst

The  main  outcomes  overall  and  according  to  baseline  ordinal  score  in  the  ITT-population,  including outcomes on time to recovery and mortality described in the publication of Beigel et. al. 2020 are shown in Table 5 below:

<div style=\"page-break-after: always\"></div>

Table 5 Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population.

|                                                         | Overall                                    | Overall                    | Ordinal Score at Baseline   | Ordinal Score at Baseline   | Ordinal Score at Baseline   | Ordinal Score at Baseline   | Ordinal Score at Baseline   | Ordinal Score at Baseline   | Ordinal Score at Baseline   | Ordinal Score at Baseline   |
|---------------------------------------------------------|--------------------------------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                                         |                                            |                            | 4                           | 4                           | 5                           | 5                           | 6                           | 6                           | /                           | /                           |
|                                                         | Remdesivir (N-541)                         | Placebo (N-521)            | Remdesivir (N-75)           | Placebo (N-63)              | Remdesivir (N-232)          | Placebo (N-203)             | Remdesivir (N-95)           | Placebo (N-98)              | Remdesivir (N-131)          | Placebo (N-154)             |
| Recovery                                                |                                            |                            |                             |                             |                             |                             |                             |                             |                             |                             |
| No. ofrecoveries                                        | 399                                        | 352                        | 73                          | 58                          | 206                         | 156                         | 57                          | 61                          | 63                          | 77                          |
| Median time to recovery (95%Cl) days                   | 10 (9-11)                                  | 15 (13-18)                 | 5 (4-6)                     | 6 (4-7)                     | 7 (6-8)                     | 9 (7-10)                    | 15 (10 27)                  | 20 (14 26)                  | 29 (24NE)                   | 28 (24NE)                   |
| Rate ratio (95% CI)                                     | 1.29 (1.12-1.49 [P<0.001])                 | 1.29 (1.12-1.49 [P<0.001]) | 1.29 (0.911.83)             | 1.29 (0.911.83)             | 1.45 (1.18-1.79)            | 1.45 (1.18-1.79)            | 1.09 (0.761.57)             | 1.09 (0.761.57)             | 0.98 (0.70-1.36)            | 0.98 (0.70-1.36)            |
| Mortality through day14                                 |                                            |                            |                             |                             |                             |                             |                             |                             |                             |                             |
| Hazard ratio for data through day 15 (95% CI)           | 0.55 (0.36-0.83)                           | 0.55 (0.36-0.83)           | 0.42 (0.04-4.67)            | 0.42 (0.04-4.67)            | 0.28 (0.12-0.66)            | 0.28 (0.12-0.66)            | 0.82 (0.40-1.69)            | 0.82 (0.40-1.69)            | 0.76 (0.39-1.50)            | 0.76 (0.39-1.50)            |
| No. of deaths by day 15                                 | 35                                         | 61                         | 1                           | 2                           | 7                           | 21                          | 13                          | 17                          | 14                          | 21                          |
| Kaplan-Meier estimate of mortality by day 15% (95% CI) | 6.7 (4.89.2)                               | 11.9 (9.415.0)             | 1.3 (0.29.1)                | 3.2 (0.8-12.1)              | 3.1 (1.5-6.4)               | 10.5 (7.0-15.7)             | 14.2 (8.523.2)              | 17.3 (11.2-26.4)            | 10.9 (6.6-17.6)             | 13.8 (9.2-20.4)             |
| Mortality overentirestudy periodi                       |                                            |                            |                             |                             |                             |                             |                             |                             |                             |                             |
| Hazard ratio (95% Cl)                                   | 0.73 (0.52-1.03)                           | 0.73 (0.52-1.03)           | 0.82 (0.17-4.07)            | 0.82 (0.17-4.07)            | 0.30 (0.14-0.64)            | 0.30 (0.14-0.64)            | 1.02 (0.54-1.91)            | 1.02 (0.54-1.91)            | 1.13 (0.67-1.89)            | 1.13 (0.67-1.89)            |
| No. of deaths by day 29                                 | 59                                         | 77                         | 3                           | 3                           | 9                           | 25                          | 19                          | 20                          | 28                          | 29                          |
| Kaplan-Meierestimateofmortality by day 29 % (95% CI)  | 11.4 (9.014.5)                             | 15.2 (12.3-18.6)           | 4.1 (1.3- 12.1)             | 4.8 (1.6-14.3)              | 4.0 (2.1-7.5)               | 12.7 (8.8-18.3)             | 21.2 (14.0-31.2)            | 20.4 (13.7-29.8)            | 21.9 (15.7-30.1)            | 19.3 (13.8-26.5)            |
| Ordinal score at day 15 (2 days)-no. (%)              | Ordinal score at day 15 (2 days)-no. (%) |                            |                             |                             |                             |                             |                             |                             |                             |                             |
|                                                         | 157 (29.0)                                 | 115 (22.1)                 | 38 (50.7)                   | 28 (44.4)                   | 90 (38.8)                   | 62 (30.5)                   | 18 (18.9)                   | 14 (14.3)                   | 11 (8.4)                    | 11 (7.1)                    |
| 2                                                       | 117 (21.6)                                 | 102 (19.6)                 | 20 (26.7)                   | 15 (23.8)                   | 70 (30.2)                   | 58 (28.6)                   | 22 (23.2)                   | 19 (19.4)                   | 5 (3.8)                     | 10 (6.5)                    |
| 3                                                       | 14 (2.6)                                   | 8 (1.5)                    | 8 (10.7)                    | 4 (6.3)                     | 6 (2.6)                     | 4 (2.0)                     | 0                           | 0                           | 0                           | 0                           |
| 4                                                       | 38 (7.0)                                   | 33 (6.3)                   | 3 (4.0)                     | 7 (11.1)                    | 17 (7.3)                    | 13 (6.4)                    | 12 (12.6)                   | 4 (4.1)                     | 6 (4.6)                     | 9 (5.8)                     |
| 5                                                       | 58 (10.7)                                  | 60 (11.5)                  | 3 (4.0)                     | 5 (7.9)                     | 25 (10.8)                   | 18 (8.9)                    | 2 (2.1)                     | 14 (14.3)                   | 28 (21.4)                   | 23 (14.9)                   |
| 6                                                       | 28 (5.2)                                   | 24 (4.6)                   | 1 (1.3)                     | 0                           | 5 (2.2)                     | 7 (3.4)                     | 12 (12.6)                   | 11 (11.2)                   | 10 (7.6)                    | 6 (3.9)                     |
| 7                                                       | 95 (17.6)                                  | 121 (23.2)                 | 1 (1.3)                     | 3 (4.8)                     | 13 (5.6)                    | 21 (10.3)                   | 16 (16.8)                   | 20 (20.4)                   | 57 (43.5)                   | 74 (48.1)                   |
| 8                                                       | 34 (6.3)                                   | 58 (11.1)                  | 1 (1.3)                     | 1 (1.6)                     | 6 (2.6)                     | 20 (9.9)                    | 13 (13.7)                   | 16 (16.3)                   | 14 (10.7)                   | 21 (13.6)                   |
| Odds ratio (95% CI)                                     | 1.5 (1.2-1.9)                              | 1.5 (1.2-1.9)              | 1.5 (0.82.7)                | 1.5 (0.82.7)                | 1.6 (1.2-2.3)               | 1.6 (1.2-2.3)               | 1.4 (0.92.3)                | 1.4 (0.92.3)                | 1.2 (0.8-1.9)               | 1.2 (0.8-1.9)               |

* P values and confidence intervals have not been adjusted for multiple comparisons. NE denotes not possible to estimate.

 Mortality over the first 14 days includes data from all patients who were still alive through 14 days postenrollment, with data censored on day 15, as if 14 days was the maximum followup time. Mortality over the entire study period uses the totality of the study data and censors data from patients who completed follow-up alive at 28 days postenrollment.

Recovery rate ratios and hazardratioswere calculated from the stratified Cox model; the Pvalueforthis ratiowascalculated with the stratifiedlog-rank test (overall model stratified by actual disease severity). Recovery rate ratios greater than 1 indicate a benefit with remdesivir; hazard ratios less than 1 indicate a benefit with remdesivir.

The ordinal score at day 15 is the patient's worst score on the ordinal scale during the previous day.Four patients died 15 days after randomization and are recorded as having died for the ordinal score at the day 15 outcome but not for the mortality day 15 outcome.Scores onthe ordinal scale are as follows: 1, not hospitalized, no limitations of activities; 2,nothospitalized,limitationofactivities,home oxygenrequirement, orboth;3hospitalized,not requiring supplemental oxygen and no longerrequiring ongoingmedical care used ifhospitalia 5, hospitalized, requiring any supplemental oxygen; 6,hospitalied, requiring noninvasive ventilaton oruse ofhigh-flow oxygen devices;7, hospitalized, receiving nvasive mechanical ventilation or extracorporealmembrane oxygenation (ECMO); and 8,death.Odds ratios and P values were calculated with the use ofa proportional odds model (overall model adjusted for actual disease severity). Odds ratio values greater than 1 indicate a benefit with remdesivir.

Beigel et al, NEJM, October 2020.

The Kaplan Meier Estimates of  survival  by  baseline  ordinal  score  and  the  respective  95  %  confidence intervals are shown in the figures below. In the overall population, the KM survival curves separated after approximately 5 days of study treatment, implying a lower mortality rate in the RDV-group versus the placebo group starting from Day 5 in the overall study population (Figure 1). The KM survival curves by baseline  ordinal  score  demonstrate  that  the  between-group  differences  in  mortality  vary  considerably according to baseline disease severity, with the largest difference seen in patients with a baseline ordinal score of 5 (Figure 3), no effect in patients with baseline ordinal score 4 (Figure 2) and 6 (Figure 4) and an increased risk of mortality in patients with baseline ordinal scale 7 (Figure 5B).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Days

Figure 1: Kaplan-Meier Estimates of Survival Overall. The widths of confidence intervals have not been adjusted for multiplicity.

<!-- image -->

Days

Figure 2: Kaplan-Meier Estimates of Survival by Baseline Ordinal Scale Category 4, The widths of confidence intervals have not been adjusted for multiplicity.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 3: Kaplan-Meier Estimates of Survival by Baseline Ordinal Scale Category 5. The widths of confidence intervals have not been adjusted for multiplicity.

<!-- image -->

Days

Figure 4: Kaplan-Meier Estimates of Survival by Ordinal Scale Category 6. The widths of confidence intervals have not been adjusted for multiplicity.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Days

Figure  5B  Kaplan-Meier  Estimates  of  Survival  by  Ordinal  Scale  Category  7.  The  widths  of  confidence intervals have not been adjusted for multiplicity.

Figures taken from Beigel et al, NEJM, October 2020.

Information on interactions between treatment effect and baseline ordinal score with respect to mortality and time to recovery are shown in Table 6 below.

Table 6: Results of Cox proportional hazards models testing for interactions between treatment effect and baseline ordinal scale with respect to mortality

| Cox Proportional Hazards Model                                                                                                                                                                                                                              | Group              | HR (95% CI)      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------|
| Mortality                                                                                                                                                                                                                                                   |                    |                  |
| Model 4 - Mortality with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as continuous Model terms: treatment, continuous baseline ordinal score,                                                           | Baseline Score 4   | 0.34 (0.15,0.76) |
| Model 4 - Mortality with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as continuous Model terms: treatment, continuous baseline ordinal score,                                                           | Baseline Score 5   | 0.50 (0.30,0.85) |
| Model 4 - Mortality with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as continuous Model terms: treatment, continuous baseline ordinal score,                                                           | Baseline Score 6   | 0.75 (0.53,1.07) |
| interaction between treatment and ordinal score                                                                                                                                                                                                             | Baseline Score 7   | 1.13 (0.71,1.79) |
| Model 5 - Mortality with interaction term for treatment effect by baseline ordinal score; Baseline ordinal scores grouped as 4/5 versus 6/7 Model terms: treatment, grouped baseline ordinal score, interaction between treatment and grouped ordinal score | Baseline Score 4/5 | 0.36 (0.18,0.70) |
| Model 5 - Mortality with interaction term for treatment effect by baseline ordinal score; Baseline ordinal scores grouped as 4/5 versus 6/7 Model terms: treatment, grouped baseline ordinal score, interaction between treatment and grouped ordinal score | BaselineScore 6/7  | 1.08 (0.73,1.62) |
| Model 6 - Mortality with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as categorical                                                                                                                     | Baseline Score 4   | 0.83 (0.17,4.13) |
|                                                                                                                                                                                                                                                             | Baseline Score 5   | 0.30 (0.14,0.64) |
| Model terms: treatment, categorical baseline ordinal score, interaction between treatment and categorical ordinal score                                                                                                                                     | Baseline Score 6   | 1.02 (0.55,1.92) |
| Model terms: treatment, categorical baseline ordinal score, interaction between treatment and categorical ordinal score                                                                                                                                     | Baseline Score 7   | 1.12 (0.67,1.89) |

<div style=\"page-break-after: always\"></div>

| Cox Proportional Hazards Model                                                                                                                                                                                                                                         | Group              | HR (95% CI)      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------|
| Recovery                                                                                                                                                                                                                                                               |                    |                  |
| Model 1 - Time to recovery with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as continuous Model terms: treatment, continuous baseline ordinal score,                                                               | Baseline Score 4   | 1.59 (1.24,2.03) |
| Model 1 - Time to recovery with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as continuous Model terms: treatment, continuous baseline ordinal score,                                                               | Baseline Score 5   | 1.37 (1.17,1.60) |
| Model 1 - Time to recovery with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as continuous Model terms: treatment, continuous baseline ordinal score,                                                               | BaselineScore 6    | 1.18 (1.00,1.40) |
| interaction between treatment and ordinal score                                                                                                                                                                                                                        | Baseline Score 7   | 1.02 (0.77,1.35) |
| Model 2 - Time to recovery with interaction term for treatment effect by baseline ordinal score; Baseline ordinal scores grouped as 4/5 versus 6/7 Model terms: treatment, grouped baseline ordinal score, interaction between treatment and grouped ordinal score     | BaselineScore 4/5  | 1.47 (1.23,1.76) |
| Model 2 - Time to recovery with interaction term for treatment effect by baseline ordinal score; Baseline ordinal scores grouped as 4/5 versus 6/7 Model terms: treatment, grouped baseline ordinal score, interaction between treatment and grouped ordinal score     | Baseline Score 6/7 | 1.03 (0.81,1.32) |
| Model 3 - Time to recovery with interaction term for treatment effect by baseline ordinal score; Baseline ordinal score treated as categorical Model terms: treatment, categorical baseline ordinal score, interaction between treatment and categorical ordinal score | BaselineScore 4    | 1.36 (0.97,1.93) |
|                                                                                                                                                                                                                                                                        | BaselineScore5     | 1.51 (1.23,1.86) |
|                                                                                                                                                                                                                                                                        | Baseline Score 6   | 1.10 (0.76,1.58) |
|                                                                                                                                                                                                                                                                        | Baseline Score 7   | 0.97 (0.70,1.36) |

## CHMP's Comment:

Not for all enrolled patients in the NIAID trial the day-28 mortality status was available. It remains unclear why the mortality status of 19 patients in the RDV group and 13 patients in the placebo group is still missing, although the 29 days after randomization have long been completed and the patients with missing status  have  not  discontinued  the  study.  As  the  mortality  status  of  patients  is  considered  important, especially for the subgroups, in which even a single death more can make a difference on whether the point estimate for mortality is for or against RDV, the MAH is asked to clarify if these patients are loss to follow up or if they are missing due to other issues, i.e. problems with data transfer from the study centre.

The Day-28 all-cause mortality data indicated a numerically lower risk of mortality for RDV in the overall population (both strata, group [RR 0.73; 95% CI: 0.52, 1.02; p = 0.066]). However, this effect is mainly driven by patients requiring supplemental oxygen (baseline ordinal score of 5).

Between  group  differences  vary  considerably  according  to  baseline  disease  severity.  Neither  for  the subgroup with a baseline ordinal score of 6 (non-invasive ventilation or high flow oxygen devices), nor for the subgroup with a baseline ordinal score of 7 (IMV or ECMO) a beneficial effect was conclusively seen: not for time to recovery (HR: 1.09; CI: 0.76, 1.57 and HR: 0.98; CI 0.70, 1.36, respectively), and neither for mortality (RR: 1.02; CI: 0.54, 1.14; p=0.949 and RR: 1.13; CI 0.67, 1.89; p = 0.652, respectively).

The models including interaction between treatment effect and baseline ordinal scale indicate a reduced or even lack of efficacy in higher ordinal scale categories (ordinal scale 6 and 7) with respect to time to recovery and mortality, while a greater treatment benefit of Remdesivir was seen in lower ordinal scale categories, especially in category 5 (whereby model 4 and model 1 including baseline score as continuous covariate clearly provide a poor fit and should be disregarded, as the proportional hazards assumption for the treatment*baseline score interaction is obviously not fulfilled).

These results would substantiate the concept of a window of opportunity for an antiviral substance, such as Remdesivir, in COVID-19. Based on the currently available data this window appears to be limited to patients in need of supplementary oxygen at high risk for disease progression but not yet suffering from more severe pulmonary affection.  An  effect  of  Remdesivir  has  not  be  observed  in  patients  with  more advanced disease, as their disease course is rather driven by the host inflammatory response than by the virus, and hence Remdesivir as antiviral drug may not have a benefit here.

In order gain further understanding of the effect of Remdesivir on mortality in the subgroup of ventilated patients in the NIAID trial, the MAH is asked to provide:

<div style=\"page-break-after: always\"></div>

- a. An  analysis  of  mortality  in  a  subgroup  of  patients  comprising  those  ventilated  at  the  time  of randomisation in the NIAID trial, including those on non-invasive ventilation, invasive ventilation and ECMO.
- b. A separate analysis of all patients that were categorised in category 6 and received non-invasive ventilation at the time of randomisation.
- c. Please provide symptom duration prior to randomisation (median +IQR) per ordinal scale stratum at baseline.
- d. Please provide data on the duration of hospitalisation prior to baseline (median + IQR) per ordinal scale stratum at baseline.
- e. Please provide key safety indices, including renal events, from the randomised NIAID-ACTT1 study for patients in baseline ordinal scale categories 6 and 7, per treatment arm.

No forest-plots on Day 28 mortality data by baseline ordinal status were provided.

## 6.2. Potential impact of Corticosteroids on treatment outcomes

Considering the reported outcomes of the Recovery study {The RECOVERY Collaborative Group, 2020}, an interest in combined use of Remdesivir and dexamethasone in the target population is anticipated. At time of the CMA, the extent of such co-administration in the NIAID-ACTT(1) study were unknown.

Now, the publication of the final results of the NIAID-ACTT1 study {Beigel et al, 2020} contains some information on the concomitant use of glucocorticoid. These are summarized below, supplemented with information from the study report, which was also submitted.

## Methods - analysis of data submitted

In the severe strata, 105 patients in the Remdesivir group (22% of the 477 patients) and 116 patients in the Placebo group (25% of the 467 patients) received a glucocorticoid (Table 7).

<div style=\"page-break-after: always\"></div>

Table 7: Concomitant Medication by Actual Disease Severity and Treatment Group (As Treated Population)

|                                           | Remdesivir (N = 532)    | Remdesivir (N = 532)   | Placebo (N = 516)       | Placebo (N = 516)   | All Subjects (N = 1048)   | All Subjects (N = 1048)   |
|-------------------------------------------|-------------------------|------------------------|-------------------------|---------------------|---------------------------|---------------------------|
|                                           | Mild- Moderate (N = 55) | Severe (N = 477)       | Mild- Moderate (N = 49) | Severe (N = 467)    | Mild- Moderate (N =104)   | Severe (N = 944)          |
| Medication/Therapies                      | n (%)                   | n (%)                  | n (%)                   | n (%)               | n (%)                     | n (%)                     |
| Antivirals                                |                         | 10 (2)                 | 2 (4)                   | 6 (1)               | 2 (2)                     | 16 (2)                    |
| Polymerase inhibitors                     |                         | 2 (<1)                 |                         | 3 (1)               |                           | 5 (1)                     |
| Protease inhibitors                       |                         | 8 (2)                  | 2 (4)                   | 3 (1)               | 2 (2)                     | 11 (1)                    |
| Corticosteroids                           | 10 (18)                 | 105 (22)               | 10 (20)                 | 116 (25)            | 20 (19)                   | 221 (23)                  |
| Other anti-inflammatory drugs             | 5 (9)                   | 37 (8)                 | 7 (14)                  | 30 (6)              | 12 (12)                   | 67 (7)                    |
| Monoclonal antibodies targeting cytokines | 1 (2)                   | 22 (5)                 | 3 (6)                   | 23 (5)              | 4 (4)                     | 45 (5)                    |
| Other biologic therapies                  | 4(7)                    | 17 (4)                 | 4 (8)                   | 9 (2)               | 8 (8)                     | 26 (3)                    |
| Potential treatments for COVID-19         | 15 (27)                 | 175 (37)               | 20 (41)                 | 181 (39)            | 35 (34)                   | 356 (38)                  |
| Hydroxychloroquine/Chloroquine            | 15 (27)                 | 169 (35)               | 19 (39)                 | 170 (36)            | 34 (33)                   | 339 (36)                  |
| Other                                     |                         | 8 (2)                  | 1(2)                    | 13 (3)              | 1(1)                      | 21 (2)                    |

N = Number of subjects in the As Treated Population.

n = Number of subjects reporting taking at least one medication in the specified category.

Source: CSR dated 23 Aug 2020, Table 10

## CHMP's comment:

Overall, in the severe strata there seems to be no important imbalances between the randomised groups with  regard to  concomitant  use of  corticosteroids. However,  data  regarding  corticosteroid  doses  is  not reported. In the Recovery study, patients were treated with a dexamethasone 6 mg once daily for up to ten days. Based on mechanism of action and course of severe viral infections it is likely that the beneficial effect of corticosteroids in these diseases is dependent on the dose administered. Singh AK et al (2020) reviewed  five  studies  on  the  role  of  steroids  for  COVID-19  reporting  variable  outcomes  and  highlight possible dose effects of steroids indicating use of lower doses might be associated with more favourable outcomes. Insofar, information regarding corticosteroid doses (e.g. low dose, high dose) is crucial but was insufficiently recorded.

In  addition,  there  was  not  differentiation  between  corticosteroids  that  were  initiated  before  and  after enrolment:

<!-- image -->

Source: Response to Questions SOB013, table req12647.15, p.114

<div style=\"page-break-after: always\"></div>

Assessing  the  influence  of  post-baseline  initiation  of  corticosteroid  treatment  is  generally  difficult  as initiation of corticosteroids depends on clinical status of a patient that can be influenced by randomized treatment such that post-baseline differences between treatment groups may be explained by effects of study treatments.

## Results

Results of an ad-hoc sensitivity analysis of the mortality outcomes to evaluate the effect of concomitant therapy that were intended as treatment for COVID-19 and were given to patients prior to and during the study are reported (Table 8).

Table 8: Time to Death through Day 15 and Day 29 by Treatment Group: Corticosteroid Sensitivity Analysis - ITT Population

<!-- image -->

|                     |           |                    |    | MedianTime   | MedianTime   | HR       | HR        |
|---------------------|-----------|--------------------|----|--------------|--------------|----------|-----------|
| SensitivityAnalysis | Study Day | TreatmentGroup     | n  | Estinate     | I0%96        | Estinate | 95%CI     |
| CorticosteroidUse   | Day 15    | Remdesivir (N=541) | 25 | NE           | NE           | 0.74     | 0.44,1.26 |
|                     |           | Placebo (N=521)    | 32 | NE           | NE           |          |           |
|                     | Day 29    | Remdesivir(N=541)  | 41 | NE           | NE           | 0.86     | 0.57,1.32 |
|                     |           | Placebo (N=521)    | 45 | NE           | NE           |          |           |

Subjects that received corticosteroid are censored at time of first corticosteroid use.

NE = Not Estimated. Median was not reached so estimates were not calculated.

N= Number of subjects in the specified treatment group.

n = Number of subjects who died by the specified study day without any prior use of corticosteroids.

HR is the ratio of the hazard of Death in each treatment group estimated from the stratified Cox model. The ratio is Remdesivir to Placebo.

Source: CSR dated 23 Aug 2020, Table 10

## CHMP's comment:

The statistical  analysis  that  was  provided  by  the  applicant  based  on  a  Cox  proportional-hazard  model including treatment, corticosteroid use, interaction term of treatment and corticosteroid use and additional covariates is considered of limited value.

In the analysis, patients were assigned to the corticosteroid group irrespectively whether treatment was initiated before or after randomization. This is not appropriate: Firstly, this leads to immortal time bias because  it  is  impossible  that  patients  died  before  initiation  of  corticosteroid  treatment.  Secondly,  the initiation of corticosteroid treatment after randomization depends on clinical status of a patient which may be influenced by treatment (Remdesivir or placebo). In addition, strata analyses (e.g. mild/moderate vs. severe) would have been required.

Overall,  any  conclusion  from  this  model  is  questionable.  In  addition,  concluding  from  a  non-significant interaction effect on no relevant interaction is not valid (absence of evidence is not evidence of absence); the point estimates and confidence intervals should also be considered where some numerical differences are seen.

## 6.3. Interim WHO SOLIDARITY trial results - Remdesivir data

In early 2020, there were no approved anti-viral treatments for COVID, and WHO expert groups advised that four re-purposed drugs, Remdesivir, Lopinavir (given with Ritonavir, to slow hepatic degradation),

<div style=\"page-break-after: always\"></div>

Interferon  (1a),  and  chloroquine  or  hydroxychloroquine  should  be  evaluated  in  an  international randomised trial. WHO SOLIDARITY trial is a large, simple, adaptive, multi-country, open label, randomised clinical trial in hospitalised adults. The protocol was designed to involve multiple potentially over-stressed hospitals  in  multiple  countries.  To  facilitate  collaborations  even  in  those  overloaded  hospitals,  patient enrolment and randomisation were done via online procedures and no paperwork was required.

On October 15, interim results of the WHO SOLIDARITY trial were published as a not-peer reviewed preprint on medrxiv. (https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1). (8)  Only interim study results concerning Remdesivir are considered relevant for this variation, i.e. mortality data, are summarised and assessed below.

## Methods - analysis of data submitted

The WHO SOLIDARITY trial is a large, simple, adaptive, multi-country, open label, randomised clinical trial in hospitalised adults diagnosed with COVID-19 to provide reliable estimates on any effects of these four alternative anti-viral treatments on in-hospital mortality in moderate and in severe COVID.

## Study population

## Main inclusion criteria

Consenting adults (age  18) hospitalised with definite COVID-19, not already receiving any of the study drugs, without known allergy or contra-indications to any of them (in the view of the physician responsible for their care), and without anticipated transfer within 72 hours to a non-study hospital. Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts were expected.

## Exclusion Criteria

Significant contra-indication to any one of the study drugs (e.g., serious chronic liver or heart disease, some concurrent medication or pregnancy).

## Data reported before randomisation

Information was entered electronically on

- Country, hospital (from a list of approved hospitals) and randomising doctor
- Confirmation that informed consent has been obtained Patient identifiers, age and sex
- Patient characteristics (yes/no): current smoking, diabetes, heart disease, chronic lung disease, chronic liver disease, asthma, HIV infection, active tuberculosis.
- COVID-19  severity  at  entry  (yes/no):  shortness  of  breath,  being  given  oxygen,  already  on  a ventilator, and, if lungs imaged, major bilateral abnormality (infiltrations/patchy shadowing)
- Whether any of the study drugs are currently NOT AVAILABLE at the hospital.

## Treatments

Four  potential  anti-viral  agents,  Remdesivir,  Chloroquine/Hydroxychloroquine,  Lopinavir  (given  with Ritonavir, to slow hepatic degradation) and Interferon (1a) were to be evaluated.

## Objectives

The protocol-specified primary objective was to assess effects on in-hospital mortality (i.e., mortality during the  original  episode  of  hospitalization;  follow-up  ceased  at  discharge)  not  only  in  all  patients  but  also

<div style=\"page-break-after: always\"></div>

subdivided by severity of disease at the time of randomization (i.e. in those with moderate COVID and in those with severe COVID (subsequently defined as ventilated when randomized)).

## Sample size

The protocol stated that: 'the appropriate sample sizes could not be estimated at the start of the trial and will depend on the evolution of the epidemic. The larger the number entered the more accurate the results will  be,  but  numbers  entered  will  depend  on  how  the  epidemic  develops.  If  substantial  numbers  get hospitalised in the participating centres, it may be possible to enter several thousand hospitalised patients with relatively mild disease and a few thousand with severe disease.' The Executive Group, blinded to any findings, decided the timing of release of interim results.

## Randomisation

Adults (age  18 years) recently hospitalised, or already in hospital, with definite COVID and, in the view of the responsible doctor, no contra-indication to any of the study drugs were randomised in equal proportions between control and whichever other study drug were locally available:

- Local standard of care alone,

OR local standard of care plus one of

- Remdesivir (daily infusion for 10 days)
- Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)
- Lopinavir with Ritonavir (orally twice daily for 14 days)
- Lopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days).

## Follow-up:

When patients die or are discharged, follow-up ceases and it is reported:

- Which study drugs were given (and for how many days)
- Whether ventilation or intensive care was received (and, if so, when it began)
- Date of discharge, or date and cause of death while still in hospital.

If no report is received within 6 weeks of study entry, an electronic reminder is sent.

## Drug safety:

Suspected  unexpected  serious  adverse  reactions  that  are  life-threatening  (e.g.,  Stevens-  Johnson syndrome,  anaphylaxis,  aplastic  anaemia,  or  anything  comparably  uncommon  and  serious)  must  be reported within 24 hours of being diagnosed, without waiting for death or discharge.

## Data monitoring:

A global Data and Safety Monitoring Committee will keep the accumulating drug safety results and major outcome results under regular review.

## CHMP's comment

Patients were classified with severe disease, if they were already ventilated at randomisation. However, the type of ventilation was not reported at study entry and remains unclear.

<div style=\"page-break-after: always\"></div>

The primary endpoint of the Solidarity trial was in-house mortality, while the key secondary endpoint in NIAID study was all-cause mortality. This has to be kept in mind, when comparisons between studies are made.

## Statistical methods

The protocol-specified primary objective was to assess effects on in-hospital mortality (i.e., mortality during the original episode of hospitalization; follow-up ceased at discharge) not only in all patients but also in those with moderate COVID and in those with severe COVID (subsequently defined as ventilated when randomized).

The four main sets of analyses involve the evenly randomized pairwise comparisons of each study drug vs its controls. The controls for those randomly allocated one particular drug were those patients who could by chance have been randomly allocated that drug (at that moment, in that hospital), but instead got allocated standard of care. If, for a particular study entrant, more than one study drug was available, allocation to standard of care would put that patient into the control group for each of them. Hence, there is partial overlap between the four control groups. Each comparison between a study drug and its controls, however,  is  evenly  randomized  (50/50)  and  unbiased,  as  both  groups  are  affected  equally  by  any differences between countries or hospitals and by any time trends in patient characteristics or standard of care.

All analyses relate mortality to allocated treatment (i.e., they are intent-to-treat analyses). The overall mortality analyses were of all randomised patients (drug vs its control), and the only protocol-specified subgroup analyses are those considering separately patients with moderate and with severe COVID (i.e., already ventilated; the type of ventilation was not recorded at study entry.)

Unstratified Kaplan-Meier methods plot 28-day risk. Death rate ratios (RRs) and p-values are from log-rank analyses, stratified for 3x2=6 strata of age and ventilation at entry. If the stratified log-rank Observed minus Expected number of deaths is O-E with variance V, logeRR is calculated as (O-E)/V with variance 1/V and a Normal distribution. The few currently uncertain death times were taken as day 7. Analyses censored patients with outcome not yet reported at day 0, and censored the few inter-hospital transfers at transfer. They did not censor patients discharged alive, as analyses were of mortality during the initial hospitalisation. Forest plots (with 95% CIs only for overall results, otherwise 99% CIs) and chi-squared statistics (sum of [O-E]2/V, with no p-value given) help interpret any apparent heterogeneity of treatment RRs between subgroups.

The Discussion includes meta-analyses of the major trial results, based on the inverse-variance-weighted average of b=logeRR from each stratum of each trial, using odds ratios where hazard or death rate ratios were unavailable. (This weighted average is derived from the sums of [O-E] and of V over strata) In general, the more deaths in a stratum the larger V is and, correspondingly, the smaller is the variance of logeRR, so the more weight that stratum gets. Homogeneity of different RRs is not needed for this weighted average to be informative.

## CHMP's comment

Only a high-level description of statistical methods was provided in this preliminary report. In the core protocol that was referred to in the report, no specific statistical methods were described. As far as it can be concluded from the information provided, statistical analyses appear overall appropriate. However, it is unclear whether any of the analyses was pre-specified. It is even unclear how the time point for analysis was determined as a sample size for primary analysis appears not to have been defined.

The study includes several comparisons: In-hospital mortality for each of the four study drug vs its controls was analyzed in the overall population but also in those with moderate and severe COVID. In addition,

<div style=\"page-break-after: always\"></div>

there were several secondary endpoints and additional subgroup analyses. It is not clear which comparisons were pre-specified and there seems to have been no strategy for type 1 error control.

The analysis set for each study drug includes the evenly randomized pairwise comparisons of each study drug vs its controls, i.e. those patients who were allocated to the specific study drug vs those who could have been allocated to it (because it was available at the hospital when patient was randomised). This is a pragmatic approach and acceptable in so far as it ensures an unbiased comparison. However, it is not fully clear  whether  these  analysis  sets  being  defined  in  dependency  of  current  drug  availability  of  specific experimental drugs at their hospitals are fully representative for the target populations.

The primary endpoint was in-hospital  mortality.  The  preliminary  report  includes  results  for  28-day  inhospital mortality but it is unclear whether the time horizon 28 days was pre-specified. Follow-up ceased at discharge. Patients discharged alive were not censored (resp. they were censored at maximal followup), which is appropriate for analysis of in-hospital mortality because discharged patients can be considered to  have  survived  hospital  stay  indefinitely  (because  it  is  known  that  they  survived  hospitalization, independently what happened afterwards). Patients were censored at inter-hospital transfer, implying the assumption that these were at the same risk of death as those patients not transferred. This is not plausible as there must be a reason for the transfer that could be related to patient's prognosis; however, this is unlikely to have a relevant influence on outcomes as there were only a 'few' transfers (exact number not given).

Outcomes not yet reported are censored at day 0 such that these are de facto excluded from analysis, assuming these patients are missing completely at random (i.e. missing independently from their outcome and prognostic factors).

The statistical methods for meta-analysis are standard methods and are in principle appropriate. However, while a systematic summary of the available evidence for RDV is clearly useful, particularly regarding effects in subpopulations, the added value of common effect estimates from a meta-analysis seems to be limited in this case, among other issues, there are e.g. differences in the definitions of subpopulations between studies.

## Results

## CHMP's comment

Only the published interim study results from the Solidarity trial concerning Remdesivir are considered relevant for this variation, i.e. mortality data, are presented and assessed below.

## Participant flow

From March 22 to October 4, 2020, 11,330 patients were entered from 405 hospitals in 30 countries in all 6 WHO regions.  Of these, 64 (0.6%) had no, or uncertain, consent to follow-up, leaving 11,266 for intentto-treat analyses of these 2750 were allocated to remdesivir (Figure 5).

After asking which treatments were locally available, random allocation (with equal probability) was between local standard of care (SoC) and  the  available  treatments.  After  excluding  64/11,330  (0.6%)  with  no/uncertain  consent  to  follow-up,  11,266  remain  in  the  ITT analyses. Each pairwise ITT analysis is between a particular treatment and its controls, i.e., those who could have been allocated it but were concurrently allocated the same management without it. There is partial overlap between the four control groups.

<div style=\"page-break-after: always\"></div>

Figure 5: WHO Solidarity Trial - information to October 4, 2020 on entry, follow-up (FU) and intent-to-treat (ITT) analyses

<!-- image -->

WHO Solidarity Trial Consortium, NEJM ,Dec 2020.

## Baseline data

Table 9 shows patient characteristics: 9120 (81%) age &lt;70 years, 6985 (62%) male, 2768 (25%) with diabetes, 916 (8%) already ventilated, and 7002 (62%) randomized on days 0-1. For each drug, patient characteristics were well balanced by the unstratified 50/50 randomization between it and its controls. Deaths were at median day 8 (IQR 4-14) and discharges at median day 8 (IQR 5-13). With 1253 deaths, the  Kaplan-Meier  estimate  of  28-day  mortality  was  11.8%.  This  risk  depended  on  several  factors, particularly age (20% if  70 years, 6% if &lt;50 years) and ventilation (39% if ventilated, otherwise 10%).

Table 9 also describes compliance. For Remdesivir the scheduled treatment period was 10 days (or to prior death or discharge). Of those allocated Remdesivir, 98.5% began treatment. Midway through this period, 96% were still taking it (as against only 2% of the Remdesivir controls).

<div style=\"page-break-after: always\"></div>

Table 9: Entry characteristics by random allocation, and compliance with that allocation Excludes 64 without clear consent to follow-up. Comparisons are of Remdesivir vs concurrent allocation to the same treatment without it, as the control group.

|                                                                      | All in any intent- to-treat analysis                                 | All in any intent- to-treat analysis                                 | All in any intent- to-treat analysis                                 | Remdesivir vs its control   | Remdesivir vs its control   |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------|-----------------------------|
|                                                                      | Entered No.                                                          | %                                                                    | No.28-d died KM%                                                     | Active                      | Control                     |
| All participants                                                     | 11266 100                                                            |                                                                      | 1253 11.8                                                            | 2743                        | 2708                        |
| Entry characteristics                                                |                                                                      |                                                                      |                                                                      |                             |                             |
| Age (years)                                                          |                                                                      |                                                                      |                                                                      |                             |                             |
| <50                                                                  | 3995                                                                 | 35                                                                   | 237 6.2                                                              | 961                         | 952                         |
| 50-69                                                                | 5125                                                                 | 45                                                                   | 618 12.8                                                             | 1282                        | 1287                        |
| 70+                                                                  | 2146                                                                 | 19                                                                   | 39820.4                                                              | 500                         | 469                         |
| Respiratory support                                                  |                                                                      |                                                                      |                                                                      |                             |                             |
| No oxygen at entry                                                   | 3204                                                                 | 28                                                                   | 78 2.5                                                               | 661                         | 664                         |
| On oxygen at entry                                                   | 7146                                                                 | 63                                                                   | 844 12.8                                                             | 1828                        | 1811                        |
| Alreadyventilated                                                    | 916                                                                  | 8                                                                    | 331 39.0                                                             | 254                         | 233                         |
| Bilateral lung lesions                                               |                                                                      |                                                                      |                                                                      |                             |                             |
| No                                                                   | 1266                                                                 | 11                                                                   | 493.7                                                                | 287                         | 259                         |
| Yes                                                                  | 8832                                                                 | 78                                                                   | 1043 12.7                                                            | 2175                        | 2153                        |
| Not imaged at entry                                                  | 1168                                                                 | 10                                                                   | 161 14.9                                                             | 281                         | 296                         |
| Prior days in hospital                                               |                                                                      |                                                                      |                                                                      |                             |                             |
| 0                                                                    | 3289                                                                 | 29                                                                   | 3199.8                                                               | 724                         | 712                         |
| 1                                                                    | 3713                                                                 | 33                                                                   | 384 10.8                                                             | 917                         | 938                         |
| 2+                                                                   | 4264                                                                 | 38                                                                   | 550 14.6                                                             | 1102                        | 1058                        |
| Geographic location                                                  |                                                                      |                                                                      |                                                                      |                             |                             |
| Europe**or Canada                                                    | 2488                                                                 | 22                                                                   | 188 7.8                                                              | 715                         | 698                         |
| Latin Americas                                                       | 1941                                                                 | 17                                                                   | 400 22.7                                                             | 470                         | 514                         |
| Asia and Africat                                                     | 6837                                                                 | 61                                                                   | 665 10.3                                                             | 1558                        | 1496                        |
| Other characteristics                                                |                                                                      |                                                                      |                                                                      |                             |                             |
| Male                                                                 | 6985                                                                 | 62                                                                   | 852 13.0                                                             | 1706                        | 1725                        |
| Current smoking                                                      | 830                                                                  | 7                                                                    | 93 11.8                                                              | 178                         | 161                         |
| History of -Diabetes                                                 | 2768                                                                 | 25                                                                   | 379 14.7                                                             | 707                         | 666                         |
| -Heart disease                                                       | 2337                                                                 | 21                                                                   | 319 14.7                                                             | 571                         | 567                         |
| - Chronic lung disease                                               | 635                                                                  | 6                                                                    | 102 17.2                                                             | 151                         | 145                         |
| - Asthma                                                             | 529                                                                  | 5                                                                    | 56 11.5                                                              | 139                         | 139                         |
| - Chronic liver disease                                              | 135                                                                  | 1                                                                    | 21 17.2                                                              | 36                          | 41                          |
| Compliancewith allocated treatment                                   | Compliancewith allocated treatment                                   | Compliancewith allocated treatment                                   | Compliancewith allocated treatment                                   |                             |                             |
| %who were taking the study drug midway through itsscheduleddurationt | %who were taking the study drug midway through itsscheduleddurationt | %who were taking the study drug midway through itsscheduleddurationt | %who were taking the study drug midway through itsscheduleddurationt | 95.8                        | 1.6                         |
| % of those reported as discharged whowerestill inhospital on: Day7   | % of those reported as discharged whowerestill inhospital on: Day7   | % of those reported as discharged whowerestill inhospital on: Day7   | % of those reported as discharged whowerestill inhospital on: Day7   | 69                          | 59                          |
| Day 14                                                               | Day 14                                                               | Day 14                                                               | Day 14                                                               | 22                          | 19                          |
| Day 21                                                               | Day 21                                                               | Day 21                                                               | Day 21                                                               | 9                           | 8                           |

Notes: The few with a particular characteristic unknown are merged with the largest category of that characteristic.

\"28-d KM %\" is the Kaplan-Meier 28-day % risk of in-hospital death. *No. died includes any in-hospital deaths after day 28.

* Interferon randomisation was interferon + Lopinavir vs Lopinavir until 4 July. then it was interferon vs standard of care.

Albania, Austria, Belgium, Finland, France, Ireland, Italy. Lithuania, Luxembourg, Macedonia, Norway. Spain, Swilzerland.

S Argentina, Brazil, Colombia, Honduras, Peru.

 Egypt, India, Indonesia, Iran, Kuwait, Lebanon, Malaysia, Pakistan, Philippines, Saudi Arabia, South Affica.

+ Compliance is calculated only among those who died or were discharged alive, and is defined as the % taking the study drug midway through its scheduled duration (or midway through the time from entry to death or discharge, if this is shorter).!

WHO Solidarity Trial Consortium, NEJM, Dec 2020.

## CHMP's comment:

With 1253 deaths, the Kaplan-Meier estimate of 28-day mortality was 11.8%. This risk depended on several factors, particularly age (20% if  70 years, 6% if &lt;50 years) and ventilation (39% if ventilated, otherwise

<div style=\"page-break-after: always\"></div>

10%). For patients already ventilated at randomisation (8%) the Kaplan-Meier estimate of 28-day mortality was 39%, compared to 10% in patients not ventilated at randomisation.

Interestingly, of those allocated Remdesivir (98.5% began treatment), midway through this period, 96% were still taking it (as against only 2% of the Remdesivir controls). Hence, compliance to the allocated treatment  duration  was  higher  in  the  SOLIDARITY  trial  than  in  the  NIAID  trial,  where  less  than  62% completed the full study course.

## Outcomes and estimation

For the pairwise comparison of Remdesivr to placebo, Figure 6 shows the unstratified Kaplan-Meier analyses of the 28-day in house-mortality. No effect of Remdesivr on the 28-day in-house mortality was seen (12.5% for RDV compared to 12.7% for control). The death rate-ratio (RR) for Remdesivir was 0.95 (0.81-1.11) with a p value of 0.50.

<!-- image -->

Nos. at risk at start of each week, and nos. dying

16

14

Control

27081262138932004431908

Figure 6: Kaplan-Meier graphs on in-house mortality.

WHO Solidarity Trial Consortium, NEJM ,Dec 2020.

In Figure 7 below death rate ratios (RRs) stratified by age and respiratory support at entry and overall RRs stratified by both are shown. Overall, when stratified by both age and respiratory support at entry no effect of Remdesivir on mortality was seen (RR: 0.95 [0.81 - 1.11] p-value = 0.50). In the subgroup of patients who were ventilated at the time of randomisation, the risk of death was increased (RR: 1.20 [0.80-1.80]), compared to those not ventilated at study entry (RR: 0.86 [0.67-1.11]).

271833

<div style=\"page-break-after: always\"></div>

Figure 7: Rate Ratio of any death stratified by age and respiratory support at entry

<!-- image -->

WHO Solidarity Trial Consortium, NEJM ,Dec 2020.

Subgroup  analyses  by  ventilation  status  at  randomisation  on  the  effect  of  Remdesivr  on  the  28-day probability of death is shown in Figure 8 below. The Kaplan-Meier estimate of death for Remdesivir in the subgroup of ventilated patients is 43% compared to 37.8 % in the control arm. The age stratified RR of death in the subgroup of patients ventilated at baseline is 1.20 [0.89-1.64, p = 0.24], compared to 0.86 [0.73-1.04; p = 0-13] in those not ventilated at study entry.

Figure 8: Kaplan-Meier graphs on in-house mortality stratified by ventilation status at baseline.

<!-- image -->

WHO Solidarity Trial Consortium, NEJM ,Dec 2020.

<div style=\"page-break-after: always\"></div>

## CHMP's comment:

In the overall analyses of the day 28 mortality data no definite effect of Remdesivir on mortality was seen, with overall p-values &gt; 0.10 and a calculated death rate ratio of 0.95 [0.85-1.11, p=0.50). Subgroup analysis stratified by both age and ventilation status at randomisation did show similar results with RR of 0.95 [0.85-1.11, p=0.50).

However, subgroup analyses stratified by ventilation status at randomisation did show an increased 28-day mortality by 20% in patients already ventilated at baseline (RR: 1.20, CI [0.89-1.64, p = 0.24] compared to  patients  not  receiving  ventilation  at  study  entry  (RR:  0.86  [0.72-1.04).  Even  when  considering  the uncertainties concerning subgroup analyses due to their limited sample sizes, the analyses indicate that Remdesivir may not be effective in the population of critically ill COVID-patients.

Rate ratios of any death stratified by age and respitatory support at entry were also analysed by entry charateristics and steroid use at any time (Figure 9).

<div style=\"page-break-after: always\"></div>

<!-- image -->

better worse

Figure 9: Rate ratios of any death, stratified by age and respiratory support at entry, Remdesivir versus Control, by entry characteristics and steroid use at any time.

WHO Solidarity Trial Consortium, NEJM ,Dec 2020.

## CHMP's comment:

No significant effect of Remdesivir use on mortality rates by geographic regions were identified. However, it is notably that the probability of death is higher in Latin America (23%), Asia and Africa (12%) than in Europe and Canada (5%), which could be related to the dynamics of the pandemic leading to over-stressed hospitals or to the quality of the health care systems in this regions. However, there is no clear evidence for differences in the treatment effect between regions (broad and overlapping confidence intervals).

<div style=\"page-break-after: always\"></div>

Different viral variants with reduced susceptibility to RDV circulating in different geographic regions could also account for the slight differences in RR seen in the different geographic regions. However, no virology data are available that could support this assumption for the Solidarity trial. However, according to the authors of the publication, additional data, including virology data were collected in the Add-on clinical trials Discovery (EU) and CATCO (Canada), which will be published separately. In general, the numbers of deaths in Europe and Canada are too small, to draw any conclusion between geographic regions.

In addition, in the subgroup of patients with chronic liver disease, mortality was 7% larger in the RDV group (RDV: 7/36, control: 6/41) (24.4% RDV vs. 17.6 % control). This finding is also supported by the higher risk of death in patients receiving RDV with chonic liver disease (24.4%) compared to those without chronic liver disease (12.3%). In contrast, in the control group the risk of death was not increased in patients with chornic  liver  disease  (12.3%)  compared  to  those  without  chronic  liver  disease  (12.7%).  However,  the confidence intervals are wide (RR 1.82 [0.35-9.45]) and the numbers of death are too small to draw any conclusions. Hepatoxicity was identified as important potential risk and is listed as Category 2 imposed additional pharmacovigilance activities in the RMP. Data addressing this issue are awaited / will be assessed within the next Renewal procedure.

The Meta-analysis of the mortality data from four different trials with random allocation of Remdesivir vs. SoC in hospitalised COVID-19 patients is shown in Figure 10. These meta-analyses included mortality data from the Solidarity trial (604 deaths in 5000 randomised), the ACTT-1 trial (136 deaths in about 1000) and two smaller trials (China trial, Simple moderate trial). Mortality results from each trial, subdivided by the initial  respiratory support are shown. The like-vs-like comparison shown below allow for the proportion already on high-flow and non-invasive ventilation or invasive ventilation at entry into ACTT-1. The number of patients already mechanically ventilated was lower in the ACTT-1 trial than those in the Solidarity trial. The combined data from all four studies resulted in an overall death ratio of Remdesvir vs control of 0.91 [0.79-1.05, p = 0.20].

<div style=\"page-break-after: always\"></div>

<!-- image -->

Forbalance,controls inthe 2:1studiescount twiceinthecontrol totals and subtotals.

Figure 10: Remdesivir vs control - Meta-analysis of mortality in trials of random allocation of hospitalised COVID-19 patients to Remdesivir or the same treatment without it

WHO Solidarity Trial Consortium, NEJM ,Dec 2020.

## CHMP's comment:

Overall,  28-day  mortality  data  are  now  available  from  four  different  trials  with  random  allocation  of Remdesivir vs. SoC in hospitalised COVID-19 patients. The systematic summary of results in subgroups across trials is very valuable for assessment of consistency across studies. However, due to the differences between studies (different endpoint definition, different definition of subgroups), the pooled estimates that were calculated across trials should be interpreted with some caution.

The meta-analysis of the day 28 mortality data from the four different trials with random allocation of remdesivir vs. SoC in hospitalised COVID-19 patients, included mortality data from the Solidarity trial (604 deaths in 5000 randomised), the ACTT-1 trial (136 deaths in about 1000) and two smaller trials (China trial, Simple moderate trial: 41 deaths). The combined data from all four studies resulted in an overall death ratio of Remdesvir vs control of 0.91 [0.79-1.05, p = 0.20].

However, in all trials including 'severely ill' and 'critically ill', a consistent trend of a different effect of Remdesivir on mortality was observed for 'severely ill' and 'critically ill' patients. In hospitalised patients receiving supplemental oxygen but not on ventilation, a trend for some benefit of Remdesivir on mortality was seen. On the other side, for more critically ill patients, in particular for those receiving ventilation, a consistent trend for an increased mortality was observed for Remdesivir in all studies (13% increase for NIAID ACTT-1, RR: 1.13 [0.57-2.23]; 20% increase for Solidarity, RR: 1.20 [0.80 - 1.80]; 40% increase for China trial, RR: 1.40 [0.20 - 9.52]).

However, between trial comparisons of the D28 mortality data from the four different trials should be interpreted with some caution, due to:

<div style=\"page-break-after: always\"></div>

1. Differences in the mortality endpoints that were used, i.e. in-hospital mortality in the Solidarity trial versus. all-cause mortality in the NIAID study.
2. The type of ventilation in the solidarity trial was not reported at the time of randomisation, hence the proportion of ventilated patients that received non-invasive ventilation, IVM or ECMO remains unclear.
3. In the NIAID trial category 6 included patients receiving high-flow oxygen and non-invasive mechanical ventilation. Hence, an analysis of all patients receiving ventilation at randomisation is not available for the NIAID.
4. In line with this, it remains unclear how many of the patients in category 6 received high-flow oxygen. In  particular,  the  subgroup  of  patients  receiving  supplemental  oxygen  (low  or  high  flow)  was  not separately analysed in the NIAID trial.
5. The post-hoc nature of the subgroup analyses according to low-risk/high-risk which increases the overall uncertainties should be taken into account both for the NIAID and the Solidarity studies.

## 6.3.1. Potential impact of Corticosteroids on treatment outcomes

As already highlighted above, considering the reported outcomes of the Recovery study {The RECOVERY Collaborative Group, 2020}, an interest in combined use of Remdesivir and dexamethasone in the target population is anticipated.

The  publication  from  the  Solidarity  study  contains  some  information  on  the  concomitant  use  of glucocorticoid.

## Methods - analysis of data submitted

During the study, 1310 patients in the Remdesivir group (47.8% of the 2743 patients) and 1288 patients in the Control group (47.6% of the 2708 patients) received a glucocorticoid (Table 10).

Table 10: Use of corticosteroids and other non-study drugs

|                      | Remdesivir vs its control   | Remdesivir vs its control   | Hydroxychloroquine vs its control   | Hydroxychloroquine vs its control   | Lopinavir vs its control   | Lopinavir vs its control   | Interferon vs its control*   | Interferon vs its control*   |
|----------------------|-----------------------------|-----------------------------|-------------------------------------|-------------------------------------|----------------------------|----------------------------|------------------------------|------------------------------|
| Corticosteroids      | 1310                        | 1288                        | 140                                 | 140                                 | 316                        | 328                        | 981                          | 1053                         |
| Number&percentage    | 47.8                        | 47.6                        | 14.8                                | 15.5                                | 22.6                       | 23.9                       | 47.9                         | 51.4                         |
| Convalescent plasma  | 52                          | 58                          | 7                                   | 3                                   | 24                         | 15                         | 43                           | 33                           |
| Anti-IL-6 drug       | 133 4.9                     | 143 5.3                     | 21 2.2                              | 18 2.0                              | 42 3.0                     | 42 3.1                     | 52 2.5                       | 68 3.3                       |
| Non-trial interferon | 3                           | 25                          | 2                                   | 1 0.1                               | 4                          | 0                          | 1                            | 26                           |
| Non-trial antiviral  | 0.1                         | 0.9                         | 0.2                                 | 54                                  | 0.3                        | 0.0                        | 0.1                          | 1.3                          |
| Number entered       | 65 2.4                      | 152 5.6                     | 62 6.6                              | 6.0                                 | 86 6.2                     | 90                         | 102                          | 144                          |
|                      | 2743                        |                             | 947                                 | 906                                 |                            | 6.6                        | 5.0                          | 7.0                          |
|                      |                             | 2708                        |                                     |                                     | 1399                       | 1372                       | 2050                         | 2050                         |
|                      | 100.0                       | 100.0                       | 100.0                               | 100.0                               | 100.0                      | 100.0                      | 100.0                        | 100.0                        |

Source: {Hongchao P et al, 2020}, Supplementary online material, Table S2

<div style=\"page-break-after: always\"></div>

## CHMP's comment:

Overall,  there  seems  to  be  no  important  imbalances  between  the  randomised  groups  with  regard  to concomitant use of corticosteroids. However, data regarding corticosteroid doses is not reported. In the Recovery study, patients were treated with a dexamethasone 6 mg once daily for up to ten days. Also, there was not differentiation between corticosteroids that were initiated before and after enrolment.

## Results

Rate ratios of any death, stratified steroid use at any time are reported in Table 10 above. This subgroup analysis did not identify any effect of Remdesivir and the concomitant use of corticosteroids on mortality (16.6% vs. 17.9%) or the rate ration of death compared to the control arm (RR: 0.95 [0.74-1.22]).

## CHMP's comment:

Notable, in the analysis patients were assigned to the corticosteroid group irrespectively whether treatment was initiated before or after randomization. In addition, subgroup analyses (e.g. based on respiratory status at entry) would have been required.

Subgroup analysis by steroid use at any time did not identify any effect of Remdesivir and the concomitant use of corticosteroids on mortality (16.6% vs. 17.9%) or the rate ration of death compared to the control arm (RR: 0.95 [0.74-1.22]). In patients not using corticosteroids a slight increase in death rates were noted in the Remdesivir group, i.e. 8.0%  vs. 6.9% in the control arm (RR 1.03 [0.69 - 1.54], assuming that concomitant corticosteroid use may be beneficial for patients. However, it has to be noted that the use of corticosteroids was not stratified between use at entry or use during treatment, hence the RR in the steroid subgroups may be somewhat biased by later steroid use.

Interestingly, the use of corticosteroids was associated with higher risk of death in both groups, Remdesivir and control (16.6% vs. 8.0% and 17.9% vs. 6.9%), which may be explained by corticosteroid treatment being preferably initiated in patients with a worse clinical status (although no definite conclusion is possible). Slight imbalance in corticosteroid use seen within the groups were noted in the Solidarity trial (47.8% used corticosteroids vs. 52.2% no corticosteroids use in the RDV group, and 47.6% Corticosteroid use vs. 52.4% not using corticosteroids in the control group).

## 6.4. Discussion

The Day-28 all-cause mortality data from the NIAID study indicated a numerically lower risk of mortality for Remdesivir in the overall population (both strata; RR 0.73; 95% CI: 0.52, 1.02; p = 0.066). However, this effect is mainly driven by patients requiring supplemental oxygen (baseline ordinal score of 5).

Between-group results vary considerably according to baseline disease severity:

- For the subgroup with a baseline ordinal score of 5 (supplemental oxygen), a beneficial effect was seen: for time to recovery (HR: 1.45; CI: 1.18, 1.79), and also for mortality (RR: 0.33; CI: 0.14, 0.64; p&lt;0.001).
- For the subgroup with a baseline ordinal score of 6 (non-invasive ventilation or high flow oxygen devices), no beneficial effect was conclusively seen: not for time to recovery (HR: 1.09; CI: 0.76, 1.57), and neither for mortality (RR: 1.02; CI: 0.54, 1.14; p=0.949).
- Also for the subgroup with a baseline ordinal score of 7 (IMV or ECMO), no beneficial effect was seen: not for time to recovery (HR: 0.98; CI 0.70, 1.36), and neither for mortality (RR: 1.13; CI

Veklury 5622 II 12

<div style=\"page-break-after: always\"></div>

0.67, 1.89; p = 0.652). In contrast, the results may be indicative of a negative trend in this patient population.

In addition, the interaction tests between treatment effect and baseline ordinal score indicates a reduced or even lack of efficacy in higher baseline ordinal scores (of 6 and 7) with respect to time to recovery and mortality.

Further subgroup analysis by baseline characteristics and steroid use at any time, did not identify any effect of Remdesivir and the concomitant use of corticosteroids on mortality (16.6% vs. 17.9%) or the rate ratio of death compared to the control arm (RR: 0.95 [0.74-1.22]). In patients not using corticosteroids a slight increase in death rates were noted in the Remdesivir group, i.e. 8.0% vs. 6.9% in the control arm (RR 1.03 [0.69 - 1.54], assuming that concomitant corticosteroid use may be beneficial for patients. However, it has to be noted that the use of corticosteroids was not stratified between use at entry or use during treatment, hence the RR in the steroid subgroups may be biased by later steroid use.

Recently pre-published interim results of the SOLIDARITY trial were published. While in the analyses of the 28-day in-hospital mortality data in the overall population no definite effect of Remdesivir on mortality was seen (RR 0.95 [0.85-1.11, p=0.50), subgroup analyses stratified by ventilation status at randomisation may also be indicate a negative trend in patients already ventilated at baseline (RR: 1.20, CI [0.89-1.64, p = 0.24] compared to patients not receiving ventilation at study entry (RR: 0.86 [0.72-1.04).

In the SOLIDARITY trial, no significant effect of Remdesivir use on mortality rates by geographic regions were identified. However, it is notably that the probability of death is higher in Latin America (23%), Asia and Africa (12%) than in Europe and Canada (5%), which could be related to the dynamics of the pandemic leading to over-stressed hospitals or to the quality of the health care systems in this regions. However, there is no clear evidence for differences in the treatment effect between regions (broad and overlapping confidence intervals).

Different viral variants with reduced susceptibility to RDV circulating in different geographic regions could also account for the slight differences in RR seen in the different geographic regions. However, no virology data are available that could support this assumption for the Solidarity trial. In general, the numbers of deaths in Europe and Canada are too small, to draw any conclusion between geographic regions.

In addition, in the subgroup of patients with chronic liver disease, mortality was 7% larger in the RDV group (RDV: 7/36, control: 6/41) (24.4% RDV vs. 17.6 % control). However, the confidence intervals are wide (RR 1.82 [0.35-9.45]) and the numbers of death are too small to draw any conclusions. However, as hepatotoxicity was identified as important potential risk and is listed as Category 2 imposed additional pharmacovigilance activities in the RMP, further data  addressing this issue are awaited  / will be assessed within the next Renewal procedure.

## Overall conclusion:

Overall, in the context of a CMA, the final D28 mortality data from the pivotal NIAID study, listed as a SOB 013, were requested in order to confirm the efficacy and safety of Remdesivir in patients on IMV or ECMO. The final D28 mortality data did not confirm the efficacy of Remdesivir in these patients (RR: 1.13; 95% CI 0.67,  1.89;  p  =  0.652).  In  contrast,  the  results  may  be  indicative  of  a  negative  trend  in  this  patient population. Thus, the applicant is requested to justify a favourable risk-benefit profile based on overall available evidence in patients on IMV or ECMO when starting Remdesivir. In addition, further clarification is sought on the provided data.

## 7. PRAC advice

## N/A

<div style=\"page-break-after: always\"></div>

## 8. Changes to the Product Information

Changes are made to the Opinion Annex II conditions as detailed in the recommendations section above. However, as SOB 013 is currently not considered fulfilled, the acceptability of changes will dependent on the responses to the request for supplementary information (RSI).

## 9. Request for supplementary information

## 9.1. Major objections

## Clinical aspects

1.-In the context of a CMA, the final D28 mortality data from the pivotal NIAID study, listed as a SOB No. 13, were requested in order to confirm the efficacy and safety of Remdesivir in patients on IMV or ECMO. The final D28 mortality data did not confirm the efficacy of Remdesivir in these patients (RR: 1.13; CI 0.67, 1.89; p = 0.652). In contrast, the results may be indicative of a negative trend in this patient population. Thus, the applicant is requested to justify a favourable risk-benefit profile based on overall available evidence in patients on IMV or ECMO when starting Remdesivir.

## 9.2. Other concerns

## Clinical aspects

- 1) Day-28 mortality status was not available for all enrolled patients in the NIAID trial. It remains unclear why the mortality status of 19 patients in the RDV group and 13 patients in the placebo group is still missing, although the 29 days after randomization have long been completed and the patients with missing status have not discontinued the study. The MAH is asked to clarify the status of these patients.
- 2) The MAH is asked to include the final Day-28 mortality data in section 5.1 of the SmPC (including mortality data by WHO score).
- 3) In order gain further understanding of the effect of Remdesivir on mortality in the subgroup of ventilated patients in the NIAID trial, the MAH is asked to provide:
- a. An analysis of mortality in a subgroup of patients comprising those ventilated at the time of randomisation  in  the  NIAID  trial,  including  those  on  non-invasive  ventilation,  invasive ventilation and ECMO.
- b. A separate analysis of all patients that were categorised in category 6 and received non-invasive ventilation at the time of randomisation.
- c. Please  provide  symptom  duration  prior  to  randomisation  (median  +IQR)  per  ordinal  scale stratum at baseline.
- d. Please provide data on the duration of hospitalisation prior to baseline (median + IQR) per ordinal scale stratum at baseline.
- e. Please provide key safety indices, including renal events, from the randomised NIAID-ACTT1 study for patients in baseline ordinal scale categories 6 and 7, per treatment arm.

<div style=\"page-break-after: always\"></div>

## 10. Assessment of the responses to the request for supplementary information

## 10.1. Major objections

## Clinical aspects

## Major Objection 1

In the context of a CMA, the final D28 mortality data from the pivotal NIAID study, listed as a SOB No. 13, were requested in order to confirm the efficacy and safety of Remdesivir in patients on IMV or ECMO. The final D28 mortality data did not confirm the efficacy of Remdesivir in these patients (RR: 1.13; CI 0.67, 1.89; p = 0.652). In contrast, the results may be indicative of a negative trend in this patient population. Thus,  the  applicant  is  requested  to  justify  a  favourable  risk-benefit  profile  based  on  overall  available evidence in patients on IMV or ECMO when starting Remdesivir.

## Summary of the MAH's response

The MAH presented the following data and considerations to support a favorable benefit-risk profile for RDV for  the  treatment of patients with coronavirus disease 2019 (COVID-19) requiring invasive mechanical ventilation or ECMO (baseline ordinal score of 7):

- In reference to patient benefit, the MAH clarified that Study CO-US-540-5776 was designed and powered  to  evaluate  time  to  recovery  for  the  entire  study  population,  not  within  specific subpopulations. The study met its primary endpoint. Given this context, the MAH maintains that statistical findings within subpopulations of the study should be interpreted with caution.
- A detailed assessment of potential risk in participants with COVID-19 requiring invasive mechanical ventilation  or  ECMO  was  performed  to  address  the  safety  concerns  outlined  in  this  objection. Multiple safety analyses reaffirmed the favorable safety profile of RDV when compared with placebo across the range of COVID-19 severities. Importantly, a negative trend associated with RDV therapy could not be identified in participants on invasive mechanical ventilation or ECMO.

Given  the  current  state  of  knowledge  regarding  the  management  of  COVID-19,  the  MAH  considers  it premature to restrict treatment with a well-tolerated antiviral such as RDV in patients requiring invasive mechanical ventilation or ECMO. The potential benefits of combining well-tolerated, direct-acting antiviral therapy  with  corticosteroids,  immunomodulatory  agents,  and  other  therapeutics  are  currently  being evaluated in critically ill patients, those with the greatest unmet medical need, in several global studies. Results are expected in the coming months, and these data will further elucidate the role of RDV and other therapies in this population.

Further details and considerations of the MAH are described below.

Study CO-US-540-5776 was designed to evaluate time to recovery as the primary endpoint. The study met its primary endpoint, with a statistically significantly shorter median time to recovery in the RDV group (10 days [95% CI: 9, 11]) than in the placebo group (15 days [95% CI: 13, 18]; recovery rate ratio 1.29; 95% CI: 1.12, 1.49; p &lt; 0.001).

Mortality was analyzed as a secondary endpoint of Study CO-US-540-5776, and the overall risk of death by Day 29 was numerically lower in the RDV group than in the placebo group (hazard ratio 0.73; 95% CI: 0.52, 1.02; p = 0.066). To identify whether any subpopulations might benefit more from RDV treatment,

<div style=\"page-break-after: always\"></div>

ad hoc analyses of time to recovery and mortality by baseline ordinal score were conducted by NIAID (Table 11). Among participants with a baseline ordinal score of 7 (hospitalized, on invasive mechanical ventilation or ECMO), the hazard ratio for mortality by Day 29 was 1.13, with a 95% confidence interval of 0.67 to 1.89. Thus, it can be stated with 95% confidence that the hazard ratio lies somewhere between 0.67 and 1.89. Given this confidence interval containing 1, it is difficult to interpret the significance of an apparent negative trend in this population and, for that reason, an in-depth assessment of safety/risk is included in this response.

Table 11: CO-US-540-5776: Time to Mortality by Day 29 by Treatment Group

|                                                                        | Overall            | Overall            | Baseline Ordinal Score 4   | Baseline Ordinal Score 4   | Baseline Ordinal Score 5   | Baseline Ordinal Score 5   | Baseline Ordinal Score 6   | Baseline Ordinal Score 6   | Baseline Ordinal Score 7   | Baseline Ordinal Score 7   |
|------------------------------------------------------------------------|--------------------|--------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                        | RDV (N = 541)      | Placebo (N = 521)  | RDV (N = 75)               | Placebo (N = 63)           | RDV (N = 232)              | Placebo (N =203)           | RDV (N =95)                | Placebo (N =98)            | RDV (N = 131)              | Placebo (N = 154)          |
| No. with known mortality status at Day 29 (% of total)                 | 508 (93.9)         | 499 (95.8)         | 72 (96.0)                  | 59 (93.7)                  | 222 (95.7)                 | 195 (96.1)                 | 87 (91.6)                  | 97 (99.0)                  | 127 (96.9)                 | 148 (96.1)                 |
| No. of deaths by Day 29 (% ofno. with knownmortality status at Day 29) | 59 (11.6)          | 77 (15.4)          | 3 (4.2)                    | 3 (5.1)                    | 9 (4.1)                    | 25 (12.8)                  | 19 (21.8)                  | 20 (20.6)                  | 28 (22.0)                  | 29 (19.6)                  |
| Hazard ratio (95% CI)                                                  | 0.73 (0.52, 1.02)a | 0.73 (0.52, 1.02)a | 0.82 (0.17, 4.07)b         | 0.82 (0.17, 4.07)b         | 0.30 (0.14, 0.64)b         | 0.30 (0.14, 0.64)b         | 1.02 (0.54, 1.91)b         | 1.02 (0.54, 1.91)b         | 1.13 (0.67, 1.89)b         | 1.13 (0.67, 1.89)b         |
| P-value                                                                | 0.066c             | 0.066c             | 0.809d                     | 0.809d                     | <0.001d                    | <0.001d                    | p6t6'0                     | p6t6'0                     | 0.652d                     | 0.652d                     |

## CI=confidenceinterval

Number with known mortality status at Day 29 is the number of participants who have data for a day on or after Day 26 or who are known to be deceased. Day 26 represents the beginning of the visit window for the Day 29 visit.

- a Hazard ratio is the ratio of the hazard of death in each treatment group estimated from the stratified Cox model. The ratio is remdesivir to placebo.
- b Hazard ratio is the ratio of the hazard of death in each treatment group estimated from the Cox model. The ratio is remdesivir to placebo.
- P-value calculated using the stratified log-rank test.

P P-value calculated using thelog-rank test.

Source: CO-US-540-5776Final CSR, Table 28

A review of safety outcome measures by baseline ordinal score was conducted by the MAH to identify any additional risks associated with RDV therapy for participants across the spectrum of COVID-19 severity, including among those on invasive mechanical ventilation or ECMO at baseline (see also the response to Question 3e, below). The results of these analyses demonstrate that the safety profile of RDV is generally comparable to placebo in participants with COVID-19 across all baseline ordinal scores, including those with a baseline ordinal score of 7 (hospitalized, on invasive mechanical ventilation or ECMO). In general, the incidence  of  AEs,  study  drug-related  AEs,  SAEs,  and  AEs  leading  to  study  drug  discontinuation  was comparable between the RDV and placebo groups within each baseline ordinal score subgroup (Table 18), and the incidence of the individual AEs (by preferred term [Table 19]) and study drug-related AEs (by preferred term [data not shown]) was generally similar between the RDV and placebo groups within each baseline ordinal score subgroup. Furthermore, the overall incidence of renal AEs (Table 20) and hepatic AEs (Table 22) was generally comparable between the RDV and placebo groups within each baseline ordinal score subgroup, and the incidence of the individual renal AEs (by preferred term [Table 21]) and hepatic AEs (by preferred term [Table 13]) was generally similar between the RDV and placebo groups within each baseline ordinal score subgroup. Thus, the MAH concluded that the detailed review of safety parameters does not reveal any negative safety trends associated with RDV therapy in participants with COVID-19, including among those receiving invasive mechanical ventilation or ECMO at baseline.

As noted in the Assessment Report, severe COVID-19 is associated with a systemic inflammatory response that  can  lead  to  lung  injury  and  multisystem  organ  dysfunction.  In  many  cases,  corticosteroids  and immunomodulators are administered to manage an excessive inflammatory response that is a consequence of severe infection. Corticosteroid use has been associated with delayed clearance of coronaviruses {Arabi 2018, Stockman 2006}. Corticosteroids have also been associated with worse clinical outcomes in cases of

<div style=\"page-break-after: always\"></div>

severe  pneumonia  caused  by  influenza  {Rodrigo  2016}.  Therefore,  it  is  reasonable  to  posit  that  the coadministration  of  a  direct-acting  antiviral  during  corticosteroid  or  immunomodulatory  treatment  of COVID-19 has the potential to provide clinical benefit, as observed in the treatment of other viral infections.

The potential benefits of combining a well-tolerated, direct-acting antiviral therapy, such as RDV, with corticosteroids,  immunomodulatory  agents,  and  other  therapeutics  are  currently  being  evaluated  in critically  ill  patients,  those  with  the  greatest  unmet  medical  need,  in  several  global  studies  (ACTIV-1 [NCT04593940],  ACTIV-3  [NCT04501978],  ACTIV-5  [NCT04583969],  ACTT-2  [NCT04401579],  ACTT-3 [NCT04492475], and I-SPY [NCT04488081]). On 19 November 2020, the United States (US) Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for baricitinib, in combination with RDV, for the treatment of COVID-19 in hospitalized patients, including those receiving invasive mechanical ventilation or ECMO. This EUA was based on favorable results from a clinical study conducted by NIAID (ACTT-2 [NCT04401579]), where the combination of RDV and baricitinib reduced time to recovery relative to treatment with RDV and placebo. Baricitinib remains an investigational therapy for use in the treatment of COVID-19, and is not authorized or approved as a stand-alone treatment for COVID-19. Additional results from this and other studies are expected in the coming months. These data will further elucidate the role of RDV, as well as other therapies, in the treatment of COVID-19 in this patient population.

The MAH concludes that RDV has demonstrated statistically significant and clinically meaningful benefit for patients with COVID-19. Analyses of efficacy in the subset of participants on invasive mechanical ventilation or ECMO at baseline are inconclusive; however, an extensive analysis of safety has shown that there are no additional risks associated with the use of RDV in this patient population. Given the current state of knowledge regarding the management of COVID-19, the MAH considers it premature to restrict treatment with a well-tolerated antiviral, such as RDV, in patients requiring invasive mechanical ventilation or ECMO. The potential benefits of combining a well-tolerated, direct-acting antiviral therapy with corticosteroids, immunomodulatory agents, and other therapeutics are currently being evaluated in critically ill patients, those with the greatest unmet medical need, in several global studies. Results are expected in the coming months, and these data will further elucidate the role of RDV and other therapies in this population.

## Assessment of the MAH's response

Remdesivir received in July 2020 a conditional marketing approval (CMA). This CMA was conditional to certain  specific  obligations.  As  part  of  the  CMA  SOB  013  was  agreed,  to  explicitly  demonstrate  the benefit/risk  of  Remdesivir  in  patients  on  on  Invasive  Mechanical  Ventilation  (IMV)  and  Extracorporeal Membrane Oxygenation (ECMO).

As part of the RSI of this variation procedure a MO was raised, in which the MAH was explicitly asked to justify a favourable risk-benefit profile based on overall available evidence in patients on IMV or ECMO when starting Remdesivir. However, the response of the MAH only addressed the potential risk/harmful effects of remdesivir in the subgroup of patients on IMV or ECMO at baseline but neither the observerd missing benefit on Time to recovery (TTR), the primary efficacy endpoint of this study, nor on mortality in patients with baseline ordinal score 7.

In view of the Rapporteur, the analyses of efficacy in the subset of participants on invasive mechanical ventilation or ECMO at baseline (ordinal score 7) do neither indicate a benefit of RDV in terms of the primary endpoint Time to recovery (HR: 0.98; CI 0.70, 1.36), nor for mortality (RR: 1.13; CI 0.67, 1.89; p = 0.652). There is also inconsistency of a beneficial effect at primary and secondary endpoints analyses among the overall study population and subjects of 'subgroup 7'. HRs obtained by Cox proportional hazard models testing for interaction between treatment*baseline ordinal scale with respect to TTR abd mortality show a clear  trend  towards  worse  outcomes  with  increasing  baseline  ordinal  scale,  though  not  statistically significant.

This is further supported by the requested additional mortality analyses for specific subgroups. The hazards

<div style=\"page-break-after: always\"></div>

of death for ventilated patients, i.e. on non-invasive ventilation, invasive mechanical ventilation or ECMO at baseline (HR: 1.12; CI 0.7, 1.82) and for those patients on non-invasive ventilation (HR: 1.11; CI 0.32, 3.83), were both similar to those reported in patients on IMV/ECMO (HR: 1.13; CI 0.67, 1.89; p = 0.652), suggesting  that  remdesivir  may  not  be  beneficial  in  patients  ventilated  at  the  time  of  RDV  treatment initiation (please refer to Question 3a and b below).

The modest variation across study subgroups in median time to randomization from symptom onset and hospitalization are in agreement with the hypothesis that participants receiving ventilation or IVM/ECMO at baseline differ from non-ventilated subjects by disease characteristics (i.e. inflammatory state associated with rapid disease progression) rather than disease history. This further supports the temporal 'window of opportunity' for Remdesivir use.

Although study ACTT-1 showed overall a statistically significant effect of RDV on time to recovery and a numerically positive trend for mortality, the findings from the subgroup analysis with baseline ordinal score 7 are of concern. No beneficial effect was seen in terms of TTR and mortality in this subgroup, which was observed across different studies. Taking the lack of evidence for a benefit in this subgroup into account, the B/R in these subgroup of patients is negative. It is also noted that based on these subgroup analyses and  clinical  experience,  several  national  treatment  guidelines  and  learned  societies  in  the  EU  do  not recommend treatment with RDV in patients receiving IMV or ECMO at baseline and with onset of symptoms more than (5 to) 10 days ago.

The ACTT-2 trial with baricitinib was cited by the MAH, but it does not provide relevant additional evidence based on the data presented here.

## Overall conclusion:

SOB 013 was explicity requested by CHMP as part of the conditional marketing authorisation in order to confirm  the  efficacy  and  safety  of  Remdesivir  in  patients  on  Invasive  Mechanical  Ventilation  (IMV)  or Extracorporeal Membrane Oxygenation (ECMO). The provided data failed to confirm a benefical effect of Remdesivir in this subset of patients.

Hence, the data submitted in the context of SOB 13, considered as key for substantiation of the therapeutic indication at the time of CMA, did not provide proof of a positive benefit/risk ratio of RDV in patients on IMV/ECMO at baseline. Therefore, in view of the CHMP, therapy of patients on IMV/ECMO at the start of therapy should no longer be indicated for RDV.

## Conclusion

Issue not resolved.

## 10.2. Other concerns

## Clinical aspects

## Question 1

Day-28 mortality status was not available for all enrolled patients in the NIAID trial. It remains unclear why the mortality status of 19 patients in the RDV group and 13 patients in the placebo group is still missing, although the 29 days after randomization have long been completed and the patients with missing status have not discontinued the study. The MAH is asked to clarify the status of these patients.

<div style=\"page-break-after: always\"></div>

## Summary of the MAH's response

The MAH clarified that Day 29 mortality status is known for 508 participants (93.9%) in the RDV group and 499  participants  (95.8%)  in  the  placebo  group  (Table  12  and  CO-US-540-5776  Final  CSR,  Table  27). Excluding those who died or recovered, 14 participants (2.6%) in the RDV group and 9 participants (1.7%) in the placebo group prematurely discontinued from the study (Table 12 and CO-US-540-5776 Final CSR, Figure 2). The remaining 19 participants (3.5%) in the RDV group and 13 participants (2.5%) in the placebo group either did not receive study drug (RDV 10 participants [1.8%]; placebo 4 participants [0.8%]; Table 12 and CO-US-540-5776 Final CSR, Figure 2) or were recovered at the time of premature discontinuation from the study (RDV 9 participants [1.7%]; placebo 9 participants [1.7%]; Table 12).

Table 12: CO-US-540-5776: Summary of Known/Unknown Mortality Status at Day 29 (ITT Population)

|                                                                 | Remdesivir (N = 541)   | Placebo (N = 521)   | Total (N = 1062)   |
|-----------------------------------------------------------------|------------------------|---------------------|--------------------|
| Known mortality status at Day 29                                | 508 (93.9%)            | 499 (95.8%)         | 1007 (94.8%)       |
| Unknown mortality status at Day 29                              | 33 (6.1%)              | 22 (4.2%)           | 55 (5.2%)          |
| Randomized,buttreatmentnot administered                         | 10 (1.8%)              | 4 (0.8%)            | 14 (1.3%)          |
| Early termination, butrecovered                                 | 9 (1.7%)               | 9 (1.7%)            | 18 (1.7%)          |
| Lost to follow-up                                               | 4 (0.7%)               | 7 (1.3%)            | 11 (1.0%)          |
| Voluntary withdrawal by participant                             | 2 (0.4%)               | 2 (0.4%)            | 4 (0.4%)           |
| Voluntary withdrawal by participant, transition to comfort care | 1 (0.2%)               | 0                   | 1 (< 0.1%)         |
| Withdrawal by investigator                                      | 2 (0.4%)               | 0                   | 2 (0.2%)           |
| Early termination, excludes death and recovery                  | 14 (2.6%)              | 9 (1.7%)            | 23 (2.2%)          |
| Voluntary withdrawal by participant                             | 6 (1.1%)               | 5 (1.0%)            | 11 (1.0%)          |
| Voluntary withdrawal by participant, transition to comfort care | 3 (0.6%)               | 2 (0.4%)            | 5 (0.5%)           |
| Adverse Event                                                   | 4 (0.7%)               | 0                   | 4 (0.4%)           |
| Transferred to another hospital                                 | 1 (0.2%)               | 1 (0.2%)            | 2 (0.2%)           |
| Withdrawal by investigator                                      | 0                      | 1 (0.2%)            | 1 (< 0.1%)         |

Participants with known mortality status at Day 29 are those who have data for a day on or after Day 26 or who are known to be deceased. Day 26 represents the beginning of the visit window for the Day 29 visit.

Source: Table req12690.14; CO-US-540-5776 Final CSR,Figure 2 and Table 27

## Assessment of the MAH's response

The question was raised because there was a discrepancy between the numbers of patients who terminated the study according to the presented patients' flow and the number of patients with available mortality status at day 29. The MAH clarified that there were three categories of patients with unknown mortality status at day 29:

- 1) Patients who were randomized but not treated (it is not clear why these patients were not followed for outcomes, which would have been required for a true ITT analysis);
- 2) Patients who terminated the study early but were considered recovered at time of study termination;
- 3) Patients who terminated the study early without recovery at termination.

Only  patients  in  category  3)  were  listed  as  'early  termination'  in  the  patient  flow,  explaining  the discrepancy. Although some aspects in study design with regard to missing data appear not to have been ideal (not following patients that were not treated, termination of 4 patients with AEs), the number of patients with missing data was low such that no relevant concerns result from missing data.

## Conclusion

Issue resolved.

<div style=\"page-break-after: always\"></div>

## Question 2

The MAH is asked to include the final Day-28 mortality data in section 5.1 of the SmPC (including mortality data by WHO score).

## Summary of the MAH's response

The MAH added the final Day 29 mortality data (presented by NIAID's baseline ordinal score and where participants with unknown mortality status at Day 29 were censored at their last study visit) to Section 5.1 of the summary of product characteristics (SmPC; Table 13). Proposed updates to the remainder of the NIAID text in SmPC Section 5.1 are planned to be included in the conditional marketing authorisation (CMA) renewal submission.

Table 13: 29-Day Mortality Outcomes by Ordinal Scalea at Baseline-NIAID

|                        | OrdinalScoreatBaseline   | OrdinalScoreatBaseline   | OrdinalScoreatBaseline   | OrdinalScoreatBaseline   | OrdinalScoreatBaseline                                        | OrdinalScoreatBaseline                                        | OrdinalScoreatBaseline                          | OrdinalScoreatBaseline                          |
|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                        | 4                        | 4                        | 5                        | 5                        | 6                                                             | 6                                                             | 7                                               | 7                                               |
|                        | Not on oxygen            | Not on oxygen            | Requiringlow-flow oxygen | Requiringlow-flow oxygen | Requiringhigh-flow oxygenornon-invasive mechanicalventilation | Requiringhigh-flow oxygenornon-invasive mechanicalventilation | Requiringinvasive mechanicalventilation or ECMO | Requiringinvasive mechanicalventilation or ECMO |
|                        | Remdesivir (N=75)        | Placebo (N=63)           | Remdesivir (N=232)       | Placebo (N=203)          | Remdesivir (N=95)                                             | Placebo (N=98)                                                | Remdesivir (N=131)                              | Placebo (N=154)                                 |
| 29-day mortality       | 4.1                      | 4.8                      | 4.0                      | 12.7                     | 21.2                                                          | 20.4                                                          | 21.9                                            | 19.3                                            |
| Hazard ratiob (95% CI) | 0.82 (0.17,4.07)         | 0.82 (0.17,4.07)         | 0.30 (0.14,0.64)         | 0.30 (0.14,0.64)         | 1.02 (0.54,1.91)                                              | 1.02 (0.54,1.91)                                              | 1.13 (0.67,1.89)                                | 1.13 (0.67,1.89)                                |

ECMO=Extracorporeal membrane oxygcnation

a Not apre-specified analysis.

b Hazard ratios for baseline ordinal score subgroups are from unstratified Cox proportional hazards models.

Source:{Beigel2020}

## Assessment of the MAH's response

The MAH included the final Day-28 mortality data in section 5.1 of the SmPC (including mortality data by WHO score) as requested. However, the proposed table is not endorsed, as only the final Day-28 mortality data relevant for the approved indication should be included in section 5.1. As RDV use is not approved for treatment  of  patients  who  do  not  require  supplemental  oxygen,  information  concerning  ordinal  scale category 4 and also category 7 should be deleted.

In addition, the proposed updates to the SmPC should be included at this procedural stage. This also applies to the restriction of the indication to patients not on IMV/ECMO.

## Conclusion

Issue not resolved.

## Question 3a

In order gain further understanding of the effect of Remdesivir on mortality in the subgroup of ventilated patients in the NIAID trial, the MAH is asked to provide:

- a. An  analysis  of  mortality  in  a  subgroup  of  patients  comprising  those  ventilated  at  the  time  of randomisation in the NIAID trial, including those on non-invasive ventilation, invasive ventilation and ECMO.

<div style=\"page-break-after: always\"></div>

## Summary of the MAH's response 3a

The  MAH  provided  an  analysis  of  time  to  Mortality  by  Day  29  by  Treatment  Group  with  non-invasive ventilation, invasive mechanical ventilation, or ECMO at the time of randomization and known mortality status (Table 14).

Table 14: CO-US-540-5776: Time to Mortality by Day 29 by Treatment Group (ITT Population - Participants with Noninvasive Ventilation, Invasive Ventilation, or ECMO at Baseline and Known Mortality Status at Day 29)

|                                | RDV (N =147)       | Placebo (N =172)   |
|--------------------------------|--------------------|--------------------|
| Death by Day 29, n (%)         | 33 (22%)           | 34 (20%)           |
| Kaplan-Meier Estimate (95% CI) | 22% (15.7%, 29.1%) | 20% (13.8%, 25.8%) |
| Hazard Ratio (95% CI)          | 1.12 (0.70, 1.82)  | 1.12 (0.70, 1.82)  |
| P-value                        | 0.631              | 0.631              |

CI=confidenceinterval;KM=Kaplan-Meier

Participantswithknownmortalitystatus at Day29are thosewhohavedatafor aday onor after Day26orwhoareknown tobe deceased.Day26represents thebeginning ofthevisitwindowfor the Day29visit.

Number of participants at risk is calculated at the beginning of interval; cumulative events and KM percent (95% CI) is calculatedattheendofinterval.

Hazard ratio is the ratio of the hazard of death in each treatment group estimated from the Cox model. The ratio is remdesivir to placebo.

P-value calculated using thelog-rank test.

Source:Table req12690.15.1

## Assessment of the MAH's response

The MAH did provided the requested analyses of time to Mortality by Day 29 by Treatment Group with Noninvasive Ventilation, Invasive Ventilation, or ECMO at Baseline and Known Mortality Status at Day 29). Based on the provided data only 21 patients in the RDV group and 24 patients in the placebo group with known mortality status were on non-invasive ventilation at baseline. The Kaplan-Meier estimate was higher in the RDV group compared to the control group (22% vs. 20%, respectively). The hazard of death in the group of patients on non-invasive ventilation, invasive ventilation or ECMO at baseline and with known mortality status at Day 29 (HR: 1.12; CI 0.7, 1.82) was similar to that seen in patients on IMV/ECMO (HR: 1.13; CI 0.67, 1.89; p = 0.652), suggesting that being ventilated at the time of RDV treatment initiation may not be beneficial. However, results for the primary endpoint Time to Recovery for the subgroup of ventilated patients (non-invasive and invasive/ECMO) are not yet available. Therefore, it remains unclear if RDV has a beneficial effect in this patient population.

The initial thought behind this question was to allow for a better comparability of the mortality results of the  NIAID  study  and  the  Solidarity  study.  However,  data  published  in  the  BMJ  journal  (A  living  WHO guideline on drugs for Covid-19; doi: https://doi.org/10.1136/bmj.m3379) indicate that of 5451 patients enroled in the Solidarity trial, 8.9% were on invasive mechanical ventilation at baseline. Hence, this means that all patients who were ventilated at baseline according to the published interim WHO Solidarity results were on IMV (487/5451 = 8.9%). Hence, data of the subgroup on IMV/ECMO at baseline are comparable between the NIAID and Solidarity trial in this regard.

## Conclusion

Issue resolved.

<div style=\"page-break-after: always\"></div>

## Question 3 b

A separate analysis of all patients that were categorised in category 6 and received non-invasive ventilation at the time of randomisation.

## Summary of the MAH's response 3 b

The MAH provided an analysis of mortality in participants who were on non-invasive ventilation at the time of randomization (Table 15).

Table 15: CO-US-540-5776: Time to Mortality by Day 29 by Treatment Group (ITT Population - Participants with Noninvasive Ventilation at Baseline and Known Mortality Status at Day 29)

|                                | RDV (N = 21)      | Placebo (N = 24)   |
|--------------------------------|-------------------|--------------------|
| Death by Day 29, n (%)         | 5 (24%)           | 5 (21%)            |
| Kaplan-Meier Estimate (95% CI) | 24% (5.6%, 42.0%) | 21% (4.6%, 37.0%)  |
| Hazard Ratio (CI)              | 1.11 (0.32, 3.83) | 1.11 (0.32, 3.83)  |
| P-value                        | 0.871             | 0.871              |

CI =confidence interval;KM=Kaplan-Meier

Participantswithknownmortalitystatus at Day29are thosewhohavedatafor aday onor afterDay26or whoareknowntobe deccased.Day26representsthebeginningofthevisitwindowfortheDay29visit.

Number of participants at risk is calculated at the beginning of interval; cumulative events and KM percent (95% CI) is calculatedattheendofinterval.

Hazard ratio is the ratio of the hazard of death in cach treatment group estimated from the Cox model. The ratio is remdesivir to placebo.

P-value calculated using thelog-rank test.

Source:Table req12690.15.2

## Assessment of the MAH's response

The MAH did provided the requested analysis of time to Mortality by Day 29 in participants who were on non-invasive ventilation at the time of randomization. The Kaplan-Meier estimate was higher in the RDV group compared to the control group (24% vs. 21%, respectively). The hazard of death in the group of patients on non-invasive ventilation and with known mortality status at Day 29 (HR: 1.11; CI 0.32, 3.83) was similar to that seen in patients on IMV/ECMO (HR: 1.13; CI 0.67, 1.89; p = 0.652), suggesting that being on non-invasive ventilation at the time of RDV treatment initiation may not be beneficial. However, results for the primary endpoint Time to Recovery for the subgroup of non-invasive ventilated patients are not yet available. Thus, it remains unclear if RDV has a beneficial effect in this patient population.

## Conclusion

Issue resolved.

## Question 3 c

Please  provide  symptom  duration  prior  to  randomisation  (median  +IQR)  per  ordinal  scale  stratum  at baseline.

## Summary of the MAH's response 3c

The MAH provided the median (Q1, Q3) duration of symptoms prior to randomization (Table 16).

<div style=\"page-break-after: always\"></div>

Table 16: CO-US-540-5776: Median (Q1, Q3) Duration of Symptoms (in Days) Prior to Randomization by Baseline Ordinal Score and Treatment Group (ITT Population)

|   Baseline Ordinal Score | Treatment            |   n |   Median | Q1, Q3   |
|--------------------------|----------------------|-----|----------|----------|
|                        4 | Remdesivir (N = 75)  |  75 |        7 | 5,10     |
|                        4 | Placebo (N = 63)     |  63 |        9 | 7,11     |
|                        5 | Remdesivir (N = 232) | 232 |        9 | 6, 12    |
|                        5 | Placebo (N = 203)    | 201 |        9 | 6,12     |
|                        6 | Remdesivir (N = 95)  |  95 |        8 | 6,13     |
|                        6 | Placebo (N = 98)     |  98 |       10 | 7,13     |
|                        7 | Remdesivir (N = 131) | 130 |        9 | 7,13     |
|                        7 | Placebo (N = 154)    | 154 |       10 | 7,14     |

Q1 = 25th percentile; Q3 = 75th percentile

Ordinal score 4 = Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring mechanicalventilation orECMO.

N = Number of participants in the ITT Population.

Eleven participants with missing ordinal score at baseline were excluded from this analysis.

Three participants had missing values in duration of symptom prior to randomization.

Duration was relative to randomization date, which was calculated as randomization date - start date of symptoms.

Source: Table req12690.13

## Assessment of the MAH's response

The MAH provided the median (Q1, Q3) duration of symptoms prior to randomization. In general, symptom duration increases with disease severity. This data in combination with the observed statistically significant effect of RDV treatment in study ACTT-1, when given during the first 10 days after symptom onset (RR: 1.37 CI. 1.14; 1.64) support the assumption that there is a temportal window of opportunity for RDV treatment early during the disease, which is not the case for patients on IMV/ECMO as those are more likely to have longer duration of symptom onset.

Interestingly, the median time from symptoms onset was shorter in the Remdesivir group as compared to the placebo group in patients with baseline ordinal score 6 and 7. Having in mind the above mentioned statistically significant effect of RDV treatment when given during the first 10 days after symptom onset (RR: 1.37 CI. 1.14; 1.64) longer duration of symptom onset in patients of the placebo group in baseline ordinal scale categories 6 and 7 might have prevented a more pronounced negative trend of RDV treatment in these patients.

## Conclusion

Issue resolved.

## Question 3 d

Please provide data on the duration of hospitalisation prior to baseline (median + IQR) per ordinal scale stratum at baseline.

## Summary of the MAH's response 3d

The MAH provided the median (Q1, Q3) duration of hospitalization prior to randomization was similar across the baseline ordinal score subgroups (Table 17).

<div style=\"page-break-after: always\"></div>

Table 17: CO-US-540-5776: Median (Q1, Q3) Duration of Hospitalization (in Days) Prior to Randomization by Baseline Ordinal Score and Treatment Group (ITT Population)

|   Baseline Ordinal Score | Treatment            |   n |   Median | Q1, Q3   |
|--------------------------|----------------------|-----|----------|----------|
|                        4 | Remdesivir (N = 75)  |  75 |        2 | 1,2      |
|                        4 | Placebo (N = 63)     |  63 |        2 | 1,2      |
|                        5 | Remdesivir (N = 232) | 232 |        2 | 1,3      |
|                        5 | Placebo (N = 203)    | 203 |        2 | 1,3      |
|                        6 | Remdesivir (N = 95)  |  95 |        2 | 1, 4     |
|                        6 | Placebo (N = 98)     |  98 |        2 | 1,4      |
|                        7 | Remdesivir (N = 131) | 131 |        2 | 1,4      |
|                        7 | Placebo (N = 154)    | 154 |        2 | 1,5      |

Q1=25th percentile;Q3=75thpercentile

Ordinal score 4 = Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring mechanicalventilationorECMO.

N = Number of participants in the ITT Population.

Eleven participants with missing ordinal score at baseline were excluded from this analysis.

Duration was relative to randomization date, which was calculated as randomization date - start date of hospitalization.

Source: Table req12690.13

## Assessment of the MAH's response

The median (Q1, Q3) duration of hospitalization prior to randomization was generally similar across the baseline ordinal score subgroups.

## Conclusion

Issue resolved.

## Question 3 e

Please provide key safety indices, including renal events, from the randomised NIAID-ACTT1 study for patients in baseline ordinal scale categories 6 and 7, per treatment arm.

## Summary of the MAH's response 3e

The MAH provided an overall summary of AEs by baseline ordinal score and treatment group (Table 18). The incidence of AEs increased with increasing baseline disease severity; however, within each baseline ordinal score subgroup, AE incidence was generally similar between the RDV and placebo groups.

<div style=\"page-break-after: always\"></div>

Table 18: CO-US-540-5776: Overall Summary of Treatment-Emergent Adverse Events by Baseline Ordinal Score and Treatment Group (As Treated Population)

|                                                  | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   |
|--------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                  | 4                      | 4                      | 5                      | 5                      | 6                      | 6                      | 7                      | 7                      |
| Participants with                                | RDV (N =75)            | Placebo (N =63)        | RDV (N =231)           | Placebo (N=202)        | RDV (N =94)            | Placebo (N=98)         | RDV (N =132)           | Placebo (N =153)       |
| AnyTEAE                                          | 26 (34.7%)             | 18 (28.6%)             | 100 (43.3%)            | 104 (51.5%)            | 65 (69.1%)             | 65 (66.3%)             | 114 (86.4%)            | 136 (88.9%)            |
| Anystudydrug-relatedTEAE                         | 4 (5.3%)               | 2 (3.2%)               | 12 (5.2%)              | 12 (5.9%)              | 5 (5.3%)               | 10 (10.2%)             | 20 (15.2%)             | 23 (15.0%)             |
| AnyTESAE                                         | 9 (12.0%)              | 10 (15.9%)             | 41 (17.7%)             | 53 (26.2%)             | 32 (34.0%)             | 43 (43.9%)             | 49 (37.1%)             | 57 (37.3%)             |
| AnyTEAE leading to discontinuation of study drug | 3 (4.0%)               | 2 (3.2%)               | 12 (5.2%)              | 24 (11.9%)             | 16 (17.0%)             | 23 (23.5%)             | 26 (19.7%)             | 28 (18.3%)             |

Adversecventswerecoded usingMedDRA23.0.

Ordinal score 4 = Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring supplemental oxygen;6=Hospitalized,on noninvasiveventilation or high-flow oxygen devices;7=Hospitalized,oninvasive mechanicalventilationorECMO.

N =Number ofparticipants in the As TrcatedPopulation.

Sourcc:Tablereq12690.12.1

The AEs reported in at least 5% of total participants by preferred term, baseline ordinal score, and treatment group are provided in Table 19. The incidence of AEs generally increased with increasing baseline disease severity; however, within each baseline ordinal score subgroup, AE incidence was generally similar between the RDV and placebo groups. A similar trend was observed in an analysis of study drug-related AEs by preferred term, baseline ordinal score, and treatment group (data not shown).

Table  19:  CO-US-540-5776:  Treatment-Emergent  Adverse  Events  Occurring  in  at  Least  5%  of  Total Participants by Preferred Term, Baseline Ordinal Score, and Treatment Group (As Treated Population)

|                                      | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore    |
|--------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|-------------------------|
|                                      | 4                      | 4                      | 5                      | 5                      | 6                      | 6                      | 7                      | 7                       |
| PreferredTerm                        | RDV (N =75)            | Placebo (N=63)         | RDV (N =231)           | Placebo (N=202)        | RDV (N=94)             | Placebo (N =98)        | RDV                    | Placebo (N =132)(N=153) |
| Glomerular filtration rate decreased | 3 (4.0%)               | 2 (3.2%)               | 22 (9.5%)              | 20 (9.9%)              | 14 (14.9%)             | 16 (16.3%)             | 21 (15.9%)             | 38 (24.8%)              |
| Haemoglobin decreased                | 5 (6.7%)               | 3 (4.8%)               | 8 (3.5%)               | 8 (4.0%)               | 14 (14.9%)             | 12 (12.2%)             | 22 (16.7%)             | 39 (25.5%)              |
| Lymphocyte count decreased           | (1.3%)                 | (3.2%) 2               | (3.5%) 8               | (7.4%) 15              | (16.0%) 15             | (13.3%) 13             | (15.9%) 21             | (15.7%) 24              |
| Respiratory failure                  | (1.3%)                 | 0                      | 14 (6.1%)              | 25 (12.4%)             | 12 (12.8%)             | 24 (24.5%)             | 10 (7.6%)              | 11 (7.2%)               |
| Anaemia                              | 2 (2.7%)               | 1 (1.6%)               | 9 (3.9%)               | 9 (4.5%)               | (1.1%)                 | 7 (7.1%)               | 30 (22.7%)             | 36 (23.5%)              |
| Pyrexia                              | (1.3%)                 | 2 (3.2%)               | 10 (4.3%)              | 11 (5.4%)              | 6 (6.4%)               | 2 (2.0%)               | 21 (15.9%)             | 19 (12.4%)              |
| Blood creatinine increased           | (1.3%)                 | 0                      | 10 (4.3%)              | 6 (3.0%)               | 6 (6.4%)               | 10 (10.2%)             | 15 (11.4%)             | 20 (13.1%)              |
| Hyperglycaemia                       | 2 (2.7%)               | 0                      | 9 (3.9%)               | 8 (4.0%)               | 7 (7.4%)               | 5 (5.1%)               | 16 (12.1%)             | 21 (13.7%)              |
| Blood glucose increased              | 2 (2.7%)               |  (1.6%)               | 14 (6.1%)              | 9 (4.5%)               | 10 (10.6%)             | 5 (5.1%)               | 13 (9.8%)              | 12 (7.8%)               |
| Acute kidney injury                  | 0                      | 1 (1.6%)               | 6 (2.6%)               | 9 (4.5%)               | 8 (8.5%)               | 7 (7.1%)               | 14 (10.6%)             | 16 (10.5%)              |
| Aspartate aminotransferase increased | 1 (1.3%)               | 1 (1.6%)               | (0.4%)                 | 11 (5.4%)              | 5 (5.3%)               | 8 (8.2%)               | 11 (8.3%)              | 13 (8.5%)               |

Adverse events were coded using MedDRA 23.0.

Multiple AEs were counted only once per participant per preferred teim.

Ordinal score 4 = Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring supplemcntal oxygen; 6=Hospitalizcd,on noninvasive ventilation or high-flow oxygcn deviccs; 7=Hospitalizcd,on invasivc mcchanical ventilation or ECMO.

Preferred terms are prescnted by descending order of the total frequencics.

N = Number of participants in the As Treated Population.

Sourcc:Table req12690.12.5

<div style=\"page-break-after: always\"></div>

An overall summary of renal AEs by baseline ordinal score is provided in Table 20. Renal impairment is associated with the underlying disease process, which is evident in the increase in renal AE incidence with increasing baseline disease severity. However, renal AE incidence was generally similar between treatment groups within the baseline ordinal score subgroup.

Table 20: CO-US-540-5776: Overall Summary of Treatment-Emergent Renal Adverse Events by Baseline Ordinal Score and Treatment Group (As Treated Population)

|                                                       | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   |
|-------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                       | 4                      | 4                      | 5                      | 5                      | 6                      | 6                      | 7                      | 7                      |
| Participantswith                                      | RDV (N = 75)           | Placebo (N =63)        | RDV (N =231)           | Placebo (N=202)        | RDV (N =94)            | Placebo (N =98)        | RDV (N =132)           | Placebo (N =153)       |
| Any renal TEAE                                        | 3 (4.0%)               | 3 (4.8%)               | 31 (13.4%)             | 30 (14.9%)             | 22 (23.4%)             | 24 (24.5%)             | 38 (28.8%)             | 61 (39.9%)             |
| Any study drug-related renal TEAE                     | 0                      | 1 (1.6%)               | 4 (1.7%)               | 1 (0.5%)               | 0                      | 2 (2.0%)               | 4 (3.0%)               | 6 (3.9%)               |
| Any renal TESAE                                       | 0                      | 0                      | 0                      | 9 (4.5%)               | 5 (5.3%)               | 4 (4.1%)               | 10 (7.6%)              | 7 (4.6%)               |
| Anyrenal TEAEleading to discontinuation of study drug | 0                      | (1.6%) 1               | (2.2%) 5               | (4.0%) 8               | (6.4%) 6               | (14.3%) 14             | (13.6%) 18             | (9.2%) 14              |

Adverse events were coded using MedDRA 23.0.

RenalAEsincludepreferred termsfromMedDRA 23.0SMQAcuteRenalFailure\"

Ordinal score 4 = Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring supplemental oxygen; 6 =Hospitalized, on noninvasive ventilation or high-flow oxygen devices;7 =Hospitalized, on invasive

mechanicalventilationorECMO.

N=Number of participants in the AsTrcatedPopulation.

Source:Tahle rea12690.12.2

Renal AEs by preferred term, baseline ordinal score, and treatment group are summarized in Table 21. Most of the renal AEs observed occurred in similar percentages of participants between the RDV and placebo groups. It is notable that there is higher incidence of glomerular filtration rate decreased among placebo participants versus RDV participants in the Category 7 subgroup.

Table  21:  CO-US-540-5776:  Treatment-Emergent  Renal  Adverse  Events  by  Preferred  Term,  Baseline Ordinal Score, and Treatment Group (As Treated Population)

|                                    | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   | BaselineOrdinalScore   |
|------------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                    | 4                      | 4                      | 5                      | 5                      | 6                      | 6                      | 7                      | 7                      |
| PreferredTerm                      | RDV (N = 75)           | Placebo (N =63)        | RDV (N =231)           | Placebo (N =202)       | RDV (N =94)            | Placebo (N =98)        | RDV (N =132)           | Placebo (N = 153)      |
| Glomerularfiltrationrate decreased | 3 (4.0%)               | 2 (3.2%)               | 22 (9.5%)              | 20 (9.9%)              | 14 (14.9%)             | 16 (16.3%)             | 21 (15.9%)             | 38 (24.8%)             |
| Blood creatinineincreased          | (1.3%) 1               | 0                      | (4.3%) 10              | (3.0%) 6               | (6.4%) 6               | (10.2%) 10             | (11.4%) 15             | (13.1%) 20             |
| Acute kidney injury                | 0                      | 1 (1.6%)               | 6 (2.6%)               | 9 (4.5%)               | 8 (8.5%)               | 7 (7.1%)               | 14 (10.6%)             | 16 (10.5%)             |
| Creatininerenalclearance decreased | 0                      | 0                      | 0                      | 2 (1.0%)               | 0                      | 0                      | 4 (3.0%)               | 4 (2.6%)               |
| Renal failure                      | 0                      | 0                      | 1 (0.4%)               | 3 (1.5%)               | 2 (2.1%)               | 0                      | 0                      | 3 (2.0%)               |
| Renal impairment                   | 0                      | 0                      | 1 (0.4%)               | 2 (1.0%)               | 1 (1.1%)               | 2 (2.0%)               | 0                      | 0                      |
| Proteinuria                        | 0                      | 0                      | 0                      | 0                      | 1 (1.1%)               | 0                      | 0                      | 1 (0.7%)               |
| Renal tubular necrosis             | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 2 (1.3%)               |
| Blood creatinine abnormal          | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 1 (0.7%)               |
| Continuous haemodiafiltration      | 0                      | 0                      | 0                      | 0                      | 0                      | 1 (1.0%)               | 0                      | 0                      |
| Glomerularfiltrationrate abnormal  | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 0                      | 1 (0.7%)               |

Adverse events were coded using MedDRA 23.0.

Renal AEs include preferred terms from MedDRA 23.0 SMQAcute Renal Failure\".

Multiple AEs were counted only once per participant per preferred term.

Ordinal score 4 =Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring

Preferred terms are presented by descending order ofthe total frequencies.

supplemental oxygen; 6=Hospitalized,on noninvasive ventilation or high-flow oxygen devices; 7=Hospitalized,on invasive

N = Number of participants in the As Treated Population.

mechanical ventilation or ECMO.

Source:Tablereq12690.12.6

<div style=\"page-break-after: always\"></div>

An overall summary of hepatic AEs by baseline ordinal score is provided in Table 22. The trend in hepatic AEs was similar to that observed for overall AEs. Incidence of hepatic AEs increased with increasing baseline disease severity, but was generally similar between treatment groups within the baseline ordinal score subgroup.

Table 22: CO-US-540-5776: Overall Summary of Treatment-Emergent Hepatic Adverse Events by Baseline Ordinal Score and Treatment Group (As Treated Population)

|                                                           | Baseline OrdinalScore   | Baseline OrdinalScore   | Baseline OrdinalScore   | Baseline OrdinalScore   | Baseline OrdinalScore   | Baseline OrdinalScore   | Baseline OrdinalScore   | Baseline OrdinalScore   |
|-----------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                                                           | 4                       | 4                       | 5                       | 5                       | 6                       | 6                       | 7                       | 7                       |
| Participants with                                         | RDV (N = 75)            | Placebo (N =63)         | RDV (N = 231)           | Placebo (N = 202)       | RDV (N =94)             | Placebo (N =98)         | RDV (N = 132)           | Placebo (N =153)        |
| Any hepatic TEAE                                          | 7 (9.3%)                | 5 (7.9%)                | 14 (6.1%)               | 26 (12.9%)              | 16 (17.0%)              | 17 (17.3%)              | 34 (25.8%)              | 32 (20.9%)              |
| Any study drug-related hepatic TEAE                       | 4 (5.3%)                | 1 (1.6%)                | 7 (3.0%)                | 9 (4.5%)                | 4 (4.3%)                | 7 (7.1%)                | 14 (10.6%)              | 15 (9.8%)               |
| Any hepatic TESAE                                         | 0                       | 0                       | 0                       | 1 (0.5%)                | 0                       | 0                       | 0                       | 0                       |
| Any hepatic TEAE leading to discontinuation of study drug | 2 (2.7%)                | 1 (1.6%)                | 3 (1.3%)                | 4 (2.0%)                | 1 (1.1%)                | 2 (2.0%)                | 4 (3.0%)                | 5 (3.3%)                |

Adverseeventswere coded usingMedDRA 23.0.

Hepatic AEs include preferred terms from MedDRA 23.0 SMQ Acute and Non-infectious Liver Events.\"\"

Ordinal score 4 = Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care; 5 = Hospitalized, requiring supplemental oxygen; 6 = Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7 = Hospitalized, on invasive mechanicalventilationorECMO.

N = Number of participants in the As Treated Population.

Source:Tablereq12690.12.3

## Assessment of the MAH's response

The MAH provided the requested key safety indices, including renal events, from the randomised NIAIDACTT1 study for patients in baseline ordinal scale categories 6 and 7, per treatment arm. Based on the provided safety analyses, the safety in the subgroup of patients on IMV or ECMO was in general similar between the two groups.

However, it has to be noted, that the numbers of study drug related AEs was generally low in the ACTT-1 study, which is not surprising as the unknown disease, the variety of comedications and the pandemic situation could seriously hamper the discern of the relationship to study drug. While the MAH concluded that there were no additional risks identified with the use of RDV in this patient population,  it has to be noted that there were more patients in category 7 with treatment emrrgent serious renal AEs and with treatment emergent renal AEs who discontinued the study drug in the RDV group compated to the control group. The results may be indicative of a negative trend in patients receiving IMV or ECMO at treatment initiation,  which  might  be  explained  by  an  increased  risk  due  to  longer  therapy  duration,  i.  e.  higher cumulative exposure. In this context it is worth noting that PRAC has started a review of a safety signal to assess reports of acute kidney injury in some patients with COVID-19 taking Remdesivir. Nevertheless, presented numbers of the ACTT-1 trial are too small to draw any conclusions on this finding. Finally, it is important to highlight that the assessement of the safety aspect of remdesivir is being very closely followed by the PRAC including also the safety signal on renal toxicity. Once the assessment is concluded, in case of any concern or finding the correspondant regulatory action will be taken.

## Conclusion

Issue resolved.

## 11. Comments from member states

Following circulation of the preliminary AR, the following comments were received from 8 MS.

<div style=\"page-break-after: always\"></div>

MS1, MS2, MS3 and MS 4 fully support the Rapporteurs proposed restricted indication.

MS5 and MS6 consider a restriction of the indication to specifically exclude patients on IMV/ECMO is not necessary.  A  warning  in  section  4.4,  stating  the  current  lack  of  benefit  in  patients  on  IMV/ECMO,  is considered to be sufficient.

MS7 and MS8 do not support the proposed changes of the SmPC (neither for 4.1 nor for 4.4).

## 12. Request for supplementary information

## 12.1. Major objections

## Clinical aspects

SOB 13, considered as key for substantiation of the therapeutic indication at the time of CMA, did not provide proof of a positive benefit/risk ratio of RDV in patients on IMV/ECMO at baseline. Therefore, therapy of patients on IMV/ECMO at the start of therapy should no longer be indicated for RDV. Consequentely, the indication should be restricted as follow (add underline to text): ' Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or non-invasive ventilation at start of treatment) (see section 5.1) .'.

## 12.2. Other concerns

## Clinical aspects

2. The proposed table of the final Day-28 mortality data in section 5.1 of the SmPC (including mortality data by WHO score) is not endorsed, as only the final Day-28 mortality data relevant for the approved indication should be included in section 5.1. Information concerning ordinal scale 4 and 7 should be deleted. In addition, the propossed updates to the SmPC should be included now and not withing the renewal procedure.

## MAH responses:

The MAH provided a new table with the correct data in SmPC Section 5.1 and an updated PI with the indication agreed by the CHMP:

' Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or non-invasive ventilation at start of treatment) (see section 5.1) .'.

Therefore, all the issues are considered solved.

## Conclusion:

<!-- image -->

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly (see above).

<div style=\"page-break-after: always\"></div>

## 13. References:

- (1) Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results,  WHO clinical trial consortium, NEJM, December 2020, https://doi.org/10.1056/nejmoa2023184 )
- (2) Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report, The RECOVERY Collaborative Group NEJM, July 2020 https://doi.org/10.1056/nejmoa2021436
- (3) Efficacy of Tocilizumab in Patients Hospitalized with Covid-19, Stone et al., NEJM Oct. 2020 https://doi.org/10.1056/nejmoa2028836,
- (4) Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID19 Pneumonia A Randomized Clinical Trial, Salvarani et al., JAMA, Oct 2020, https://doi.org/10.1001/jamainternmed.2020.6615
- (5) Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19, Gupta et al., Oct. 2020, JAMA https://doi.org/10.1001/jamainternmed.2020.6252
- (6) FDA Fact sheet for healthcare provider Bamlanivimab. https://c212.net/c/link/?t=0&amp;l=en&amp;o=29755111&amp;h=1388363115&amp;u=http%3A%2F%2Fpi.lilly.co m%2Feua%2Fbamlanivimab-eua-factsheet-hcp.pdf&amp;a=Fact+Sheet+for+Healthcare+Providers
- (7) Remdesivir for the Treatment of Covid-19 - Final Report. John H. Beigel et al., N Engl J Med. 2020 Oct 8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/?report=classic
- (8) WHO SOLIDARITY trial were published as a not-peer reviewed preprint on medrxiv. (https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1).